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ABSTRACT 
Genetic Imbalances in Endometriosis Detected by Oligonucleotide-Array Based 
Comparative Genomic Hybridization 
by 
Natalie Burke 
Endometriosis is one of the most common gynecological diseases as it is thought to 
affect up to 15% of the female population. Characterized by the growth and proliferation 
of endometrial tissue outside of the uterine cavity, it is a complex condition with varying 
degrees of severity and can affect multiple regions of the body with symptoms ranging 
from a total lack of symptoms to debilitating pain and infertility. The most accepted 
theory of how endometriosis initiates is that of retrograde menstruation; however, 
approximately 90% of women with unobstructed fallopian tubes are thought to have 
some menstrual debris in the peritoneal cavity. Therefore, this theory does not explain 
in full why endometriosis occurs in some but not all women who experience retrograde 
bleeding.   
 
Genetic factors are thought to play a major role in the pathogenesis of endometriosis as 
women with a family history are 5 to 10 times more likely to develop the disease. The 
goal of this study was to determine if common chromosomal aberrations in the form of 
additions, deletions, or regions of loss of heterozygosity that may contribute to the 
establishment or progression of the disease are present in a population of 
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endometriosis patients. DNA was isolated from the peripheral blood of endometriosis 
patients and endometriosis tissue biopsies, and it was analyzed using oligonucleotide 
based array comparative genomic hybridization. The results suggest that an addition on 
chromosome 17p13.3 may play a role in the biological mechanisms involved in 
endometriosis as it was identified in 75% of the DNA samples obtained from the 
peripheral blood and 100% of the DNA samples obtained from the tissue biopsies. This 
chromosomal imbalance is of particular interest as it is located in a region that harbors 
the tumor suppressor gene, hypermethylated in cancer-1 (HIC-1), whose aberrant 
expression has been reported in multiple cancers.   
 
Endometriosis has long been thought of as a benign disease despite its malignant 
characteristics, and individuals with endometriosis have been demonstrated to have an 
increased chance of developing ovarian cancer. This was the first study to examine the 
DNA from endometriosis patients using oligonucleotide based array comparative 
genomic hybridization to investigate genetic abnormalities in endometriosis. The 
findings may provide a novel target for future therapeutic options as well as indicate a 
link between endometriosis and cancer that has not been previously reported. 
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CHAPTER 1 
INTRODUCTION 
Endometriosis is a disease involving the female reproductive organs.  Each 
month during a woman’s menstrual cycle, the uterine lining, the endometrium, grows 
and thickens in order to prepare for the implantation of a fertilized oocyte. If a fertilized 
oocyte does not implant, the endometrium is shed by way of menstruation. In most 
women a portion of the endometrium is refluxed through the fallopian tubes and out into 
the peritoneal cavity, an occurrence known as retrograde menstruation.  In some 
women, these misplaced cells are able to attach to nearby tissues where they mimic the 
normal endometrium-growing, thickening, and shedding in response to the hormonal 
fluctuations of the menstrual cycle. Whereas the menstrual debris inside of the uterus 
exits the body through the vagina, menstrual debris shed from the ectopic endometrium 
remains in the abdominal cavity. Endometriosis refers to this condition in which 
endometrial tissue grows and proliferates outside of the uterine cavity.  
Endometriosis is one of the most common gynecological diseases among 
women of reproductive age. It can be a debilitating condition associated with persistent 
inflammation as well as chronic pain in the pelvic region of many patients. Additional 
symptoms may include dyspareunia, dysmenorrhea, dysuria, dyschezia, long or heavy 
periods, and short menstrual cycles.  It is a complex disease with varying degrees of 
severity and can affect multiple regions of the body.  Endometriosis is most often found 
on the tissues surrounding the uterus (Figure 1) such as the ovaries, rectum, bladder, 
and the bowels; however, cases have been reported at locations distant from the uterus 
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such as in the lymph nodes, brain, lungs, liver, and in the eyes.  Between 10% and 15% 
of the female population 1, 2 is thought to be affected by the disease; however, these 
estimates may be conservative as many women are asymptomatic or fail to seek 
medical treatment.   
It is a major cause of discomfort as well as a common cause of infertility. Various 
studies suggest that the disease may compromise fertility by creating a hostile 
environment that affects spermatozoa, oocytes, and embryos in multiple ways. 
Distortion of the female reproductive anatomy, altered folliculogenesis   3, 4, decreased 
oocyte quality 5, increased production of reactive oxygen species  6, immune system 
alteration 7, 8, a decrease in endometrial receptivity and oocyte implantation 9, 10, 
interference with spermatozoa’s ability to fertilize an oocyte 11, 12, and dyspareunia 
resulting in abstaining from sexual intercourse have all been identified as key 
contributing factors to decreased fertility in patients with endometriosis.  
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Figure 1 Female reproductive anatomy including the most common sites for 
endometriosis to occur 
 
 
Disease Stages 
The American Society of Reproductive Medicine (ASRM) has established a 
grading system to diagnose disease severity. Points are given based on the size, 
location, and severity of the implants. A stage of I, II, III, or IV is assigned based on the 
overall score with I being minimal disease and IV being the most severe. Interestingly, 
the stage of disease does not necessarily correlate with the level of pain experienced by 
the patient as cases of asymptomatic women with advanced, widespread endometriosis 
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have been reported as well as patients experiencing severe pelvic pain with minimal 
disease.   
The physical appearance of endometriosis can vary widely and typically changes 
as the disease tissue ages. Small pink to red implants, powder burn spots, clusters of 
hemorrhagic lesions, and endometriotic cysts are the most common forms of 
endometriosis observed upon laparoscopic examination. Endometriosis tissue may be 
comprised of stroma, glandular structures, hemosiderin deposits, and fibrotic scar tissue 
with varying degrees of vascularization and hemorrhage.   
 “Raspberry” implants or small red patches or polyps of tissue are common with 
recent or young disease tissue or minimal cases of disease (Figure 2).  
Figure 2 Raspberry endometriosis implants: (A, B) Endometriosis tissue is indicated 
by black arrows. 
A.               B.  
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Powder burn or “blueberry” lesions are the most recognizable form of 
endometriosis and thus the most well documented. These spots are generally dark red, 
purple, or black in color and are generally associated with moderate to severe 
endometriosis (Figure 3).  
Figure 3 Powder burn endometriosis lesions: (A, B) Endometriosis tissue is 
indicated by black arrows. 
A.    B.    
 
Hemmorhagic lesions or red patches are easily recognized during certain phases 
of the menstrual cycle as they proliferate and shed menstrual debris with hormonal 
fluctuations (Figure 4). 
Figure 4 Hemmorhagic endometriosis lesions: (A, B, C) Endometriosis tissue is 
indicated by black arrows. 
 
A.     B.     C.  
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 “Chocolate” cysts or endometriomas are cystic structures filled with old blood 
and menstrual debris which give them their characteristic color (Figure 5). These 
structures are generally associated with severe or advanced stages of disease and 
have the potential to rupture and form adhesions.  
Figure 5 Chocolate endometriosis cysts: (A, B) Endometriosis cysts 
A.                   B.  
 
Adhesions are bands of scar tissue that form as a result of endometriosis, 
however, they are not considered endometriosis themselves (Figure 6). Extensive 
adhesion formation has the potential to cause distortion of the reproductive anatomy, 
pelvic pain, and infertility.   
Figure 6 Adhesions associated with endometriosis: Adhesions are indicated by 
black arrows. 
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Proposed Mechanisms of Pathogenesis 
Retrograde menstruation is one of the oldest and most widely accepted 
hypotheses as to how endometriosis establishes 13. Retrograde menstruation is a 
phenomenon in which a portion of the uterine lining moves into the fallopian tubes and 
out into the peritoneal cavity during menstruation rather than being shed through the 
vagina, where it attaches and grows in various locations. This misplaced endometrial 
tissue acts in the same way the normal endometrium does inside of the uterus. Over the 
course of a typical menstrual cycle as hormones fluctuate, the ectopic tissue thickens in 
preparation for the implantation of an embryo, and it is shed if implantation of an embryo 
does not occur. The ectopic implants release menstrual debris into the peritoneal cavity 
and surrounding environment until it is cleared by immunological responses or 
reabsorbed into surrounding tissue. Approximately 90% of menstruating women with 
unobstructed fallopian tubes have menstrual debris in the peritoneal cavity 14; however 
as stated, only around 15% of women of reproductive age suffer from endometriosis. 
This theory, therefore, does not explain in full why endometriosis occurs in some but not 
all women who experience retrograde menstruation. Also, this does not answer the 
question of how endometriosis is able to invade tissues outside of the pelvis. 
Coelomic metaplasia describes a scenario in which “normal” epithelial cells 
transform into abnormal endometrial cells in the peritoneal cavity or elsewhere, and 
these cells progress into endometriosis. This hypothesis stems from the notion that the 
reproductive organs form from cells lining the coelomic cavity; therefore, any 
dedifferentiated cells or remnants of this process have the ability to become endometrial 
cells and eventually form endometriosis.  As other hypotheses of pathogenesis rely on 
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endometrial tissue being present, this scenario is an attractive explanation as cases of 
endometriosis have been reported in individuals lacking uterine structures including 
women with agenesis reproductive organs 15 and in men with prostate cancer 16.  
Immunological factors have been implicated in endometriosis as most women 
experience retrograde menstruation, but only some develop the disease. It is possible 
that an inability of the immune system either to recognize or to clear refluxed menstrual 
debris may contribute to disease establishment 17 as immune system alterations have 
been demonstrated in multiple studies 18-20. This hypothesis does not address why 
endometriosis patients have not been shown to experience a higher prevalence of other 
diseases that would be expected to result from an inefficient immune system or why 
endometriosis is found in regions of the body outside of the peritoneal cavity.  
Stem cells have recently been implicated as a possible contributing factor to the 
pathogenesis of endometriosis 21-23. The endometrium is highly regenerative as the 
uterine lining thickens and is shed each month with the menstrual cycle. As with any 
tissue that undergoes rapid turnover or constant renewal, the endometrium contains a 
population of undifferentiated cells or stem cells. When necessary, chemical signals are 
sent within each microenvironment to tell these stem cells to differentiate into progenitor 
cells that will then further differentiate into the appropriate cell type- in this case, new 
endometrial lining is formed.  
It has been suggested that because stem cells are able to differentiate into a 
variety of cell types, those in circulation throughout the body may differentiate into 
endometrial cells. As these endometrial cells are aberrantly placed, they have the 
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potential to grow and establish endometriosis. Such a mechanism could potentially 
contribute to other proposed mechanisms of pathogenesis including coelomic 
metaplasia as well as explain how endometriosis establishes at sites outside of the 
peritoneal cavity in premenarchal girls and in individuals lacking female reproductive 
organs.  
Surgical contamination has been proposed to cause endometriosis wherein 
during surgical procedures involving the reproductive tract, some cells may be 
transferred into the abdominal or peritoneal cavity 24-27. These misplaced cells are 
thought to have the potential to form endometriosis lesions or implants. This mechanism 
cannot explain endometriosis in patients who have not had surgery involving the 
reproductive tract or who have never undergone surgery.  
Environmental factors including exposure to dioxins and polychlorinated 
biphenyls (PCBs) have been suggested to be correlated with endometriosis 28. These 
“organochlorines” are pollutants produced as a result of manufacturing processes and 
are known to accumulate in foods and are toxic at high concentrations. Some patients 
with endometriosis have been reported to have elevated levels of dioxins in the blood 29, 
plasma 30 and peritoneal fluid 31 when compared to control individuals. The mechanisms 
by which organochlorines may contribute to the disease remain to be elucidated at this 
point.  
Genetic factors are thought to play a major role in the pathogenesis of the 
disease as women with a family history of endometriosis are 5-10 times more likely to 
develop the disease than those without a family history 32. Multiple studies have 
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identified chromosomal imbalances in association with the disease using array based 
technology 33-36 while other similar studies identified no alterations 37, 38. Linkage studies 
have implicated various regions in the genome including loci at 7p15.2 39 and 10q26 40, 41 
with endometriosis; however, despite these studies, few commonalities have been 
noted. In this study we use a higher resolution platform than has been previously used 
to investigate the presence of genomic imbalances in the DNA from endometriosis 
tissue and corresponding peripheral blood samples of endometriosis patients. 
Summary: It is highly likely that endometriosis is a multifactorial disease with 
various components that contribute to disease establishment and severity. Despite all of 
the hypotheses proposed, investigators agree that something is different either within 
the diseased individual or in the disease tissue itself which allows the ectopically placed 
endometrium to grow and proliferate.  
 
A Benign Condition? 
Endometriosis has long been thought of as a benign disease despite its many 
similarities to cancer including metastasis, tissue invasion, angiogenesis, and 
uncontrolled cell growth. Currently, the literature suggests that the malignant 
transformation of endometriosis is between 0.3% and 5% while endometriosis 
synchronous with ovarian cancer is around 20%. Specific criteria to qualify 
endometriosis as becoming malignant were put forth in 1925 by Sampson 42 and were 
amended in 1953 by Scott 43. These criteria are as follows and are still accepted today: 
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1) Endometriosis must be located in the vicinity of a malignant tumor 
2) Malignant tissue must come directly from endometriosis tissue  
3) Tissue similar in appearance to endometrial tissue surrounding  
characteristic glands must be present 
4) There must be histological evidence of a benign to malignant  
transformation  
Because the criteria to classify endometriosis as becoming cancerous are so 
strict, chances are the incidence of malignant transformation is grossly underestimated. 
Many investigators have speculated that endometriosis patients are at a higher risk of 
developing certain cancers, and multiple studies have confirmed that women with 
endometriosis are at an increased risk of developing ovarian cancer 44-46, specifically 
endometrioid, clear-cell, and low-grade serous types.  One such study recently 
investigated women undergoing in vitro fertilization (IVF) treatment and their incidence 
of endometriosis and ovarian cancer and reported that nulliparous women with 
endometriosis had a 3-fold increase in ovarian cancer incidence 47. Identifying an 
increased risk of cancer as well as potential molecular and genetic similarities between 
ovarian cancer and endometriosis may help explain if women with endometriosis are, in 
fact, predisposed to malignancy or if endometriosis may be a precursor to ovarian 
cancer.  
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CHAPTER 2 
LITERATURE REVIEW 
Genome Wide Association and Linkage 
Gene linkage studies are useful when a genetic association is suspected in a 
particular disease, but no information is available as to its loci. Typically, large numbers 
of clinical records are accessed and analyzed with various software programs to identify 
common genetic markers in the disease group that may serve as a directional tool for 
identifying a gene or group of genes responsible for disease.  Although only few linkage 
studies have been performed on endometriosis, several potentially important 
susceptibility loci have been reported.  
Areas of linkage on chromosome 10q26 have been reported in 2 studies 40, 41. 
Painter et al. identified a linkage peak specifically within the cytochrome P450 subfamily 
C gene (CYP2C19) that is of particular interest as it is involved in the production and 
metabolism of estrogen that is known to be associated with endometriosis.  Genetic 
linkage has also been reported on chromosome 7p15.2 39 in a region upstream from 2 
possible causative genes- NFE2L3 that is expressed in the placenta and HOXA10 
which is involved in uterine development. Other areas of suggested linkage include 
chromosome 20p13 and areas of minor linkage on chromosomes 2, 6, 8, 12, 14, 15, 
and 17 40. Uno et al. reported linkage on chromosome 9p21 that includes several genes 
of potential importance including CDKN2BAS or ANRIL (antisense non-coding RNA in 
the INK4 locus) that has been reported to be altered in a variety of diseases including 
several cancers and P14 and P16 that are known tumor suppressors 48.  In the same 
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study, 2 single nucleotide polymorphisms (SNPs) were identified on chromosome 1p36 
that may be of interest as they are located within the WNT4 gene which is associated 
with development of the reproductive organs.   
Using these studies as directional markers may be useful in discovering genetic 
markers or alterations that may contribute to the disease. Many of the regions reported 
in the aforementioned studies correlate with the typical disease state of endometriosis 
as it is an estrogen-dependent disease often affecting the reproductive organs. 
Although no definitive genes have been discovered at this point that cause 
endometriosis, identifying linkage in areas associated with estrogen metabolism, the 
development of reproductive organs, and tumor suppressor genes may prove to be 
valuable pieces of the puzzle of the disease mechanism.  
 
Comparative Genomic Hybridization Microarray 
Comparative genomic hybridization (CGH) microarray is a powerful tool used to 
analyze the DNA from a patient paired with a known control DNA to investigate the 
presence of copy number variants throughout the genome. Various platforms are 
available for research including printed or oligo arrays that use a slide spotted with 
specific DNA sequences spanning the genome or fluorescent in-situ hybridization 
(FISH) based platforms in which a mixture of probes is allowed to hybridize directly to 
metaphase chromosome spreads. In either case, hybridization of each fluorescently-
labeled DNA sample is analyzed using specialized software to investigate areas of 
increased or decreased fluorescence that may correspond to areas of gains or losses of 
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genetic material. Different types of probes are available for use including oligonucleotide 
(oligo) probes and bacterial artificial chromosome (BAC) probes.  Oligos are generally 
around 30 base pairs in length while BACs are much larger and thus not able to detect 
small changes at a high resolution. Resolution refers to both the size of the probes and 
the distance between the probes, and it represents the smallest copy number variant 
size that is detectable by a platform given these 2 factors. Several studies have been 
performed using comparative genomic hybridization array technology to analyze the 
presence of copy number variants in the DNA from endometriosis patients. The most 
relevant are summarized in Table 1 and discussed below.  
 
Table 1 Studies involving comparative genomic hybridization microarray and 
endometriosis  
Group Date DNA source Platform Areas of interest 
Saare et al. 2012 Blood, eutopic/ectopic 
tissue 
Illumina Human OmniExpress 
BeadChip SNP arrays: oligo probes 
None 
Veiga-Castelli 
et al. 
2010 Eutopic/ectopic tissue FISH/metaphase CGH: oligo probes 1p33-pter, 11q12-q13.1, 
17p11.1-p12, 17q25-
qter, 19, 20q11.23-qter, 
and 22q11.2-qter. 
Zafrakas et al. 2008 Ectopic tissue  Affymetrix GeneChip: BAC probes None 
Wu et al. 2006 Eutopic/ectopic tissue Spectral Genomics Array: BAC 
probes 
1p, 5p, 6p, 6q, 11p, 16q 
Guo et al. 2004 Eutopic/ectopic tissue Spectral Genomics microarray: BAC 
probes 
1p, 3p14, 10q26, 13q33, 
22q 
Gogusev et al.  2000 Endometriosis cell 
line: FbEM-1 
FISH/metaphase CGH 1q, 5p, 6p, 6q, 9, 11p, 
12, 13q, 17q, 18, X 
Gogusev et al. 1999 Ectopic tissue FISH/metaphase CGH 1p, 5p, 6q, 7p, 17q, 22q 
 
 
Gogusev et al. used CGH to investigate copy number variants from 18 ectopic 
tissue samples of various types including peritoneal implants, nodules, and ovarian 
endometriomas in patients with advanced stages of disease 33. DNA was isolated from 
manually dissected tissue without PCR amplification.  Labeled DNA was hybridized to 
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“normal” metaphase spreads, and fluorescence was assessed for variation using 
appropriate software. Chromosomal imbalances were reported in 15 of 18 (83%) of the 
cases analyzed. The researchers recognized that small imbalances are not able to be 
observed using this methodology and noted that small chromosomal changes that may 
contribute to disease establishment and progression may still be present. Gains were 
seen on chromosomes 6q and 17q; however, losses were noted more frequently on 
chromosomes 1p, 5p, 6q, 7p, and 22q. Interestingly, many of the deletions identified 
were in regions containing tumor suppressor genes, specifically those on 1p, 5p, and 
6q. Of most interest was the loss on chromosome 1p found in 50% of cases that 
contains several tumor suppressor genes reported to be altered in various cancers 
including liver, breast, and colon cancer.  
  In 2000, the same group used similar methodology to examine chromosomal 
aberrations in an endometriosis cell line (FbEM-1) 49. The cell line was initiated from an 
ovarian endometrioma from a patient with advanced endometriosis. In contrast to their 
previous studies, gains were reported more often than losses. The most significant 
gains were shown on chromosomes 1q, 5p, 6p, and 17q, and various oncogenes were 
suggested to be involved.  Losses were evident on 6q, 9, 11p, 12, 13q, 18, and X, many 
in regions harboring tumor suppressor genes. 
Guo et al. examined 5 endometriosis tissue samples with 5 tissue samples from 
women with no history of endometriosis using a BAC array from Spectral Genomics 
which contained 995 BAC clones 50. Laser capture microdissection (LCM) was used to 
obtain epithelial cells and whole genome amplification was performed prior to 
hybridization.  Genomic alterations were reported in each endometriosis tissue sample; 
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however, no commonalities were found in all samples. Additions on chromosomes 
3p14, 10q26, and 13q33 and losses on chromosomes 1p and 22q were observed most 
frequently.  
Wu et al. used a similar microarray platform to analyze eutopic and ectopic tissue 
samples from 5 patients. This array contained 2,632 BAC clones with a resolution of 
approximately 1 Mb 36. Laser capture microdissection was used to isolate single 
endometrial epithelial cells, and whole genome amplification was performed prior to 
array hybridization. Alterations in both tissues were reported for all 5 patients. Genomic 
gains on chromosome 1p, 6p, 6q, and 11p, and genomic losses on 1p, 5p, 6q, and 16q 
were noted most frequently. Tissues were subdivided by type/location as either 
peritoneal implants or ovarian cysts. It was reported that endometriotic lesions at 
different locations may contain distinct copy number variants as the 3 peritoneal 
implants analyzed shared gains in 1p and both ovarian cysts shared losses in 6q, 7p, 
11q, and 25q. 
Zafrakas et al. examined 10 endometriotic lesions using the Affymetrix Gene 
Chip, a BAC array containing 5,659 clones with a resolution of approximately 1 Mb 37. 
DNA was isolated from homogenized tissue samples prior to hybridization. They found 
no copy number variants in any of the samples analyzed. 
 Veiga-Castelli et al. examined ectopic and eutopic tissue samples from 10 
patients using FISH/metaphase CGH 35. Five samples showed no alterations in either 
the ectopic or the eutopic tissue. One patient showed a single gain in 17p in only the 
ectopic tissue sample. One patient had gains on chromosome 19 and 22 in only the 
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eutopic tissue sample. The remaining 3 patients showed chromosomal aberrations in 
both tissue samples. Investigators reported “significant alterations” in the form of 
chromosomal gains in regions 1p33-pter, 11q12-q13.1, 17p11.1-p12, 17q25-qter, 19, 
20q11.23-qter, and 22q11.2-qter. Alterations at 11q, 17p, 17q, and 19p were observed 
most frequently, and the gain at 19p was observed in 4 samples from 3 patients. As 
40% of the cases presented in this study showed alterations in both eutopic and ectopic 
tissue samples, it was suggested that genomic alterations which may contribute to the 
disease are present not only in disease tissue but also in the eutopic endometrium and 
possibly throughout the cells of an individual.  
Saare et al. analyzed copy number variants in blood, eutopic, and ectopic tissue 
using Illumina Human OmniExpress BeadChip SNP arrays that include a total of 
733,202 SNPs spanning the genome at approximately 2.2kb intervals 38. Genomic DNA 
was isolated from peripheral blood and tissue following laser capture microscopy (LCM).  
Researchers reported copy number variants ranging in size from 3 to 340 kb; however, 
none were found to be significant. Loss of heterozygosity was also examined in this 
study and reported to be of no significance. 
Despite the fact that numerous studies have employed CGH technology to 
investigate chromosomal changes in the DNA from endometriosis patients, the findings 
thus far are unclear. The platforms used to this point identify copy number variants of a 
range of sizes and are set to discard any chromosomal changes less than 200,000 base 
pairs. For these reasons, it is difficult to compare the results of these studies as the 
resolutions are inconsistent and potentially significant small changes such as 
microadditions and microdeletions were not considered.   
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Loss of Heterozygosity 
Each gene is coded for by 2 alleles at a specific chromosomal location. Loss of 
heterozygosity (LOH) refers to a genetic alteration in which one allele for a gene is 
inactivated or deleted leaving only one functional allele. When a mutation occurs in the 
remaining allele, the gene is rendered inactive or, in some cases, the remaining allele is 
duplicated resulting in 2 copies of the dysfunctional allele. In cases of uniparental 
disomy, 2 copies of a chromosome or a portion of a chromosome are inherited from one 
parent resulting in 2 identical alleles. Each of these cases results in a homozygous 
situation or areas of LOH. Large regions of LOH have been related to the development 
of various types of cancer due largely to the loss of function of tumor suppressor genes 
in affected regions. Many studies have been performed to investigate the presence of 
loss of heterozygosity in the blood and ectopic tissue of endometriosis patients, and 
they are summarized below in Table 2. 
 
 
 
 
 
 
 
33 
 
Table 2 Studies involving loss of heterozygosity and endometriosis 
Group Date DNA source: Isolation method Areas of 
interest 
Wang et al. 2012 Ectopic tissue- fresh tissue: LCM, MCM 9p21.3, 
17q21.31 
Xu et al. 2011 Ectopic tissue-  paraffin embedded: MCM 9p, 10q, 13p 
Ali-Fehmi et al. 2006 Ectopic tissue , paraffin embedded: LCM 10q23.3 
Prowse et al. 2006 Ectopic tissue-  paraffin embedded: LCM 5q11.2, 
6p24.3, 
13q31, 17q22 
Prowse et al.  2005 Ectopic tissue- formalin fixed: LCM 8p22 
Bischoff et al. 2002 Ectopic tissue-fresh, paraffin-embedded, Peripheral 
blood 
17q 
Goumenou et al. 2001 Ectopic/eutopic tissue- paraffin embedded: LCM 9p21 
Nakayama et al. 2001 Ectopic tissue-paraffin embedded-MCM 9q22 
Sato et al. 2000 Ectopic /eutopic tissue- paraffin embedded: LCM 10q23 
Jiang et al. 1996 Ectopic tissue, fresh/frozen- paraffin embedded: LC M 9p, 11q, 22q 
 
Jiang et al. evaluated 40 endometriosis samples for 15 microsatellite markers 
known to be associated with various epithelial cancers 51. Cells were obtained from 
either frozen or paraffin embedded samples and endometriotic glandular and stromal 
cells were collected by microdissection prior to DNA extraction and PCR amplification. 
Regions of loss of heterozygosity were reported in 27.5% of the samples. Chromosomal 
regions 9p, 11q, and 22q were reported most often. Of particular interest was the region 
of LOH on 9p21 that has been reported to be present in 50% of ovarian cancer tumors 
previously. 
Sato et al. examined benign endometrial cysts consistent with endometriosis as 
potential precursors to endometrioid carcinomas and ovarian clear cell carcinomas by 
investigating loss of heterozygosity on 10q23.2 52. DNA was extracted from paraffin-
embedded tissue after LCM followed by PCR amplification. Microsatellite markers were 
used for 3 sites on chromosome 10q23.3 to examine LOH in the PTEN gene as well as 
regions flanking the gene. PTEN was targeted for analysis due to its known role as a 
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tumor suppressor gene that has been shown to be altered in multiple cancers. Loss of 
heterozygosity was observed in 13 of 23 (57%) of the endometrial cysts. Ovarian 
carcinomas and clear cell carcinomas synchronous with endometriosis were examined 
and DNA from each tissue was analyzed. Ovarian carcinomas with coexisting 
endometriosis displayed LOH in 3 of 5 cases while clear cell carcinomas concurrent 
with endometriosis showed LOH in 3 of 7 cases in both tissues. Results of this study not 
only show LOH events on 10q23.2 in regions flanking the PTEN gene in endometriosis 
tissue but also in cancerous tissue associated with it.  
More recently, LOH on 10q23 in endometriosis was revisited by Ali-Fehmi et al. 
using the same microsatellite markers as Sato’s group 53. Microscope slides of various 
lesions were analyzed, and typical and atypical endometriosis cells were included for 
analysis in addition to ovarian cancer cells.  “Typical” endometriosis cells were defined 
as having endometrial glands and stroma while “atypical” endometriosis cells were 
defined as having “architectural and cytological atypia” in addition to endometrial 
stroma. LOH was reported in 7 of 23 (30%) typical endometriosis cells and 3 of 12 
(25%) atypical endometriosis cells compared to 8 of 20 (40%) ovarian cancer cells and 
6 of 12 (50%) clear cell carcinomas. Of particular interest was the significant increase in 
LOH at marker D10S608 in cancer cells versus endometriosis cells. This marker is 
located in the region telomeric to the PTEN gene. This finding was not reported 
previously and may be important in the transition from noncancerous to cancerous cells.  
Microsatellite analysis was used by Goumenou et al. to investigate allelic 
imbalance in 22 ectopic and eutopic tissue samples from patients with endometriosis 54. 
DNA was obtained from microdissected paraffin-embedded samples and amplified by 
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PCR. Seventeen microsatellite markers previously reported to be associated with 
ovarian neoplasms were chosen for investigation. Loss of heterozygosity was reported 
in 36% of cases and most often at 9p21 in 27.3% of samples. This region is associated 
with the p16Ink4 and GALT genes that have been previously associated with infertility, 
ovarian dysfunction, and endometriosis and may play a role in disease establishment 
and progression. Additional regions reported to show some incidence of allelic 
imbalance include APOA2 and TP53 that have both been shown to occur in ovarian 
cancer.   
The same year, Nakayama et al. investigated the presence of LOH in 4 
endometriosis tissue samples using 8 microsatellite markers in various tumor 
suppressor genes 55. DNA was extracted from endometriosis cells obtained by manual 
capture microdissection (MCM) from formalin fixed, paraffin embedded tissue samples. 
LOH was seen in only one sample in the PTCH gene, a tumor suppressor previously 
reported to be altered in various cancers including basal cell carcinoma. 
Due to previous reports of alterations of chromosome 17 in endometrial and 
ovarian cancers and the similarities between endometriosis and cancer, Bischoff et al. 
chose to examine chromosome 17 for LOH events in advanced endometriosis tissue  56. 
Fresh tissue as well as archived tissue was obtained followed by DNA extraction and 
PCR amplification. LOH was determined by separating alleles on a sequencing gel and 
was reported to be present in 4 of 15 samples (27%). Three samples had losses at 
17q22-24 and one at 17q11-12. Both regions harbor tumor suppressor genes including 
BRCA1. 
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Prowse et al. investigated regions of LOH in endometriosis tissue from 17  
affected patients 57. DNA was obtained from tissue blocks and LCM was used to isolate 
endometriosis cells prior to extraction and PCR amplification. Twelve microsatellite 
markers were chosen for analysis based on regions believed to play a role in 
tumorigenesis. LOH was observed in only one sample at 8p22. The next year, the same 
group expanded their study by looking for commonalities between endometriosis tissue 
and endometriosis associated ovarian cancer (EAOC) using 82 microsatellite markers 
spanning the autosomal chromosomes 58.  Ten samples were collected from paraffin 
embedded endometriosis and EAOC tissue, and cells were selected for DNA extraction 
and PCR amplification by LCM. Twenty-two LOH events were observed in the 
endometriosis tissue, all of which were present in the corresponding EAOC samples 
indicating a possible molecular link between the 2 disease states. Alterations on 
chromosomes 5q11.2, 6p24.3, 13q31, and 17q22 were reported most often. 
Researchers suggested that these regions may contain tumor suppressor genes that 
may play a role in the transition to cancer; however, no particular genes were identified 
at the time of the study.  
In an attempt to investigate the potential role of LOH in the malignant 
transformation of ovarian endometriosis to ovarian cancer, Xu et al. examined the DNA 
from both disease tissues 59. DNA was extracted from tissue in paraffin blocks and 
manually microdissected to obtain various cell types for investigation before PCR 
amplification. Thirteen microsatellite markers flanking various tumor suppressor genes 
were analyzed using fluorescent-labeling techniques. Loss of heterozygosity events 
were reported in 5 out of 12 ovarian endometriosis samples at locations 9p, 10q, and 
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13q. These events included regions near tumor suppressor genes p16INK4a and PTEN 
that have been suggested to contribute to malignant transformation in cases of 
advanced disease. 
Wang et al. investigated the potential contribution of LOH in the ectopic 
endometrium from 54 patients with endometriosis by looking at 15 microsatellite 
markers upstream or downstream of genes that had been previously associated with 
ovarian cancer 60. Cells were obtained by either LCM, MCM, or routine dissection. DNA 
was extracted and amplified using restriction and circularization-aided rolling circle 
amplification (RCA-RCA). In samples collected by LCM, 59% showed 1 or more region 
of LOH, 36% showed 2 or more, and 5% showed 3 or more. Chromosomal regions 
showing the highest LOH frequency were 9p21.3 and 17q21.31 with 17q21.31 having 
the highest frequency of 24%. Both regions have been shown to be altered in multiple 
cancers. The region 9p21.3 contains the gene methlythioadenosine phosphorylase 
(MTAP) that has been shown to be altered in endometrial cancer 61. The region 
17q21.31 contains the gene ETS variant 4 (ETV4) that is altered in ovarian and prostate 
cancers 62 and the ADP-ribosylation factor-like 4D (ARL4D) gene shown to be altered in 
breast and ovarian cancers 63. 
Chromosome 9p was identified as having regions of LOH in 50% of the studies 
summarized. This area is of particular interest as it has been associated with multiple 
carcinomas including ovarian cancer. Aberrations on chromosome 17 were reported in 
one-third of the studies. LOH may imply that a portion of DNA has been deleted leaving 
only one allele. If this is the case, study methods such as comparative genomic 
hybridization may be able to detect the aberration. LOH can occur without a change in 
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copy number wherein an allele is deleted followed by the duplication of its sister allele or 
in cases of uniparental disomy. Study methods such as SNP arrays that are capable of 
recognizing balanced alterations are necessary to identify such regions. Regions of 
LOH have been linked to cancer, in addition, current research suggests a correlation 
between endometriosis and malignancy. Examining the link between loss of 
heterozygosity and endometriosis may fill in the mechanistic blanks between 
endometriosis and its potential role in cancer.  
 
Gene Expression Microarray 
Expression microarrays employ much of the same technology as DNA 
microarrays except that they measure the mRNA levels of multiple genes rather than 
looking at the genes themselves. Various studies have been performed on 
endometriosis blood and tissue to investigate the up- or down-regulation of various 
genes in an attempt to gain a better understanding of the disease (Table 3). More of 
these types of studies have been performed than in any other area to date as DNA 
microarrays and LOH platforms are currently being optimized. 
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Table 3 Studies involving expression microarrays and endometriosis 
Authors Date RNA Source Findings 
Chen et al. 2012 Eutopic endometrial tissue -Up-regulation of 10 genes (MAP2A)  
Kahn et al. 2012 Eutopic and ectopic tissue -Increasing number of down-regulated 
genes with advancing stages of disease 
-Common expression alterations in both 
tissues, down-regulation of genes 
associated with immune response, cell 
cycle control, and DNA repair 
 
Sundqvist et al.  2012 Eutopic endometrial tissue from 
disease/nondisease patients and 
ectopic tissue 
-Down-regulation of ApoE, JAM-1, 
LAMCI 
-Genes altered related to adhesion, cell 
proliferation, and survival 
    
Gentilini et al. 2011 Peripheral blood before and after 
surgical intervention 
-Up-regulation of 26 genes (FOS, 
RHOB) 
-Down-regulation of 15 genes 
-Genes altered related to inflammatory 
response 
Zafrakas et al. 2008 Eutopic and ectopic tissue -Up-regulation of 56 genes (immune 
response, tumor suppressors) 
-Down-regulation of 75 genes (cell cycle 
control and homeostasis) 
Eyster et al.  2007 Eutopic and ectopic tissue -717 differentially expressed genes  
Mettler et al. 2007 Eutopic and ectopic tissue -Up-regulation of ISLR, p450arom, HLA, 
SH3 
-Down-regulation of KCC, COX, RPL, 
p43  
Flores et al. 2006 Peripheral blood lymphocytes -Up-regulation of IL-2RG 
-Down-regulation of LOX-L1 
Matsuzaki et al. 2006 Eutopic and ectopic tissue -Up-regulation of17βHSD2,  COUP-TF2, 
HSP90A, PDGFA,  
Matsuzaki et al. 2005 Eutopic and ectopic tissue 
 
-Up-regulation of genes implicating 
RAS/RAF/MAPK pathway 
 
It has recently been suggested that the “normal” endometrium of women with 
endometriosis may share genetic alterations with endometriosis tissue 35, 64, 65, 65. If this is 
true, the “normal” endometrium of endometriosis patients may differ from the 
endometrium of women without the disease.  To investigate this hypothesis, Matsuzaki 
et al. examined the gene expression in the endometrium from 12 endometriosis patients 
and 12 control individuals 66. As different genes are expressed at different levels 
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depending on the stage of the menstrual cycle 67, stromal and endometrial biopsies 
were obtained from women during the late proliferative, and early, mid, and late 
secretory stages of the menstrual cycle. Of 1,176 genes investigated, none were found 
to be differentially expressed in both sets of tissues during all stages; however, several 
genes were found to be up-regulated in the epithelial cells in the late secretory phase of 
the menstrual cycle of women with the disease. The results implicated molecular 
pathways that may contribute to the disease state including the RAS/RAF/MAPK 
pathway that is involved in antiapoptotic activity within the cell.   
In 2006, the same group used similar methodology to investigate the expression 
levels of 12 genes in ovarian endometriosis that had been found to be aberrantly 
expressed in deep infiltrating endometriosis 68. It has been suggested that different 
forms of endometriosis may represent different disease entities, so comparing the 
profiles between types of endometriosis may provide valuable information into the 
intricacies of the disease. Twelve patients were included, half of which were in the 
proliferative and half in the secretory phase of the menstrual cycle. Multiple similarities 
were found between deep infiltrating endometriosis and ovarian endometriosis when 
compared to “normal” endometrium. Increases in both platelet-derived growth factor 
receptor alpha (PDGFA) and heat-shock protein 90 alpha (HSP90A) in both ectopic 
tissues might make them attractive targets for future therapies. Differences between the 
tissues included an increase in nuclear receptor superfamily 2 (COUP-TF2) and 17β-
hydroxysteroid dehydrogenase type-2 (17βHSD2) both of which contribute to 
suppressing estrogen production. These observations may indicate that estrogen levels 
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in ovarian endometriosis are lower than those observed in deep infiltrating 
endometriosis possibly indicating different disease mechanisms.   
In an attempt find molecular markers for diagnostic testing of endometriosis, 
Flores et al. investigated differences in gene expression in the peripheral blood from 6 
endometriosis patients with various stages of disease and compared them to the 
peripheral blood from 5 control individuals 69. Of approximately 15,000 genes examined, 
2 genes were shown to be differentially expressed at a significant level. Common 
gamma chain (IL-2RG), which is involved in the initiation of immune response, was up-
regulated. This finding had been shown previously in animal models of endometriosis 
and may indicate an elevated immune response in endometriosis patients. Lysyl 
oxidase-like 1 (LOXL1), which is involved in collagen metabolism, was down-regulated. 
As LOXL1 is a tumor-suppressor gene, its decrease in endometriosis may contribute to 
uncontrolled cellular growth and tumor formation that are associated with the disease.  
 Mettler et al. studied the expression profiles of both eutopic and ectopic 
endometrium samples from women during the proliferative phase of the menstrual cycle 
70. Of 1,176 genes, 9 were up-regulated and 4 were down-regulated in ectopic tissue. 
Up-regulated genes that were suspected to contribute to disease  include 
immunoglobulin superfamily containing leucine-rich repeat (ISLR) that is involved in cell 
adhesion, aromatase p450 (p450-AROM) that aids in the synthesis of estrogen, major 
histocompatibility antigen class I (HLA) that is involved in immune response, and src 
homology 3 (SH3) which  plays a role in folliculogenesis and development.  Down-
regulated genes of importance included K-Cl cotransporter that has been linked to 
reproductive function as well as cytochrome c oxidase (COX), ribosomal protein L 
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(RPL35), and tRNA synthetase complex-interacting multifunctional protein-1 (p43) 
whose functions in endometriosis are currently unknown.  
Later the same year, Eyster et al. expanded on the expression profiles previously 
done by examining 53,000 mRNA products in eutopic and ectopic endometrial tissue 
from 11 patients with endometriosis 71. Nine of the women were in the proliferative 
phase when biopsies were collected, one was in early secretory phase, and one had an 
inactive endometrium due to drug treatment. Seven-hundred seventeen genes were 
shown to be differentially expressed in endometriosis tissue when compared to 
corresponding “normal” endometrium. Of the genes reported, many were involved in 
processes that were thought to contribute to the establishment and progression of 
endometriosis. The most dramatic changes were seen in phospholipase A2 group IIA 
(PLAII2) that was increased by 153-fold, claudin 11 (CLDN11) that was increased by 
32-fold, haptoglobin (Hp) that was increased by 29-fold, and prostacyclin synthase 
(PGS) that was increased by 27-fold. Genes involved in immune and inflammatory 
response, cell adhesion, cytoskeletal organization, extracellular matrix remodeling, 
signal transduction, and embryonic development were all reported to be expressed at 
aberrant levels in ectopic endometrium. 
Investigating the molecular similarities between endometriosis and cancer, 
Zafrakas et al. examined 10 tissues from endometriosis patients with moderate to 
severe stages of disease in the proliferative phase of the menstrual cycle and compared 
them to eutopic endometrium biopsies from the same patients 37. The platform used 
covered over 40,000 genes and identified 56 up-regulated genes involved mainly in 
immune response and in tumor suppressor genes as well as 75 down-regulated genes 
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involved in cell cycle control and homeostasis. These results suggest that endometriosis 
may not be a precursor to cancer as previously suggested 72. 
Chen et al. used cDNA representational difference analysis (cDNA-RDA) to 
examine the gene expression in endometrial tissue samples from 40 women with 
endometriosis and 40 “control” women with no gynecological issues. This technique had 
not been previously used in this area of research 73. All samples were collected during 
the secretory phase of the menstrual cycle. Ten genes were reported to be up-
regulated, 4 of which have been reported previously.  Genes associated with adhesion, 
cell growth, and apoptosis were reported to have altered expression with the most 
significant change in methionine adenosyltransferase II, alpha (MAT2A). Up-regulation 
of MAT2A has been associated with various cancers and is of great interest as 
endometriosis has many malignant characteristics.  
Investigating the gene expression profile before and after surgical intervention for 
endometriosis, Gentilini et al. used a microarray platform with 17, 665 probes spanning 
the genome 74. Four patients with severe endometriosis were included and 41 genes 
were identified as being differentially expressed including 26 up-regulated genes and 15 
down-regulated genes. Of interest was the up-regulation of FBJ murine osteosarcoma 
viral oncogene homolog (FOS) that functions as an oncogene and transcriptional 
regulator and ras homolog family member b (RHOB) that functions as a transcriptional 
regulator and mediator of apoptosis. Other genes associated with inflammatory 
response were shown to be altered supporting the theory that endometriosis is an 
inflammatory-associated disease. This study was the first of its kind that indicates 
surgical treatment may alter gene expression associated with disease.  
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Fassbender et al. combined proteomics and expression array analysis to 
examine gene expression in eutopic and ectopic endometrial tissue samples from 31 
women with endometriosis and eutopic endometrial tissue from 18 control individuals 75. 
Women in both menstrual and the early and late luteal phases of the cycle were 
included. No changes in expression were reported in the eutopic endometrium from 
either group between cycle phases. There were significant changes in the expression of 
683 genes in the endometriosis tissue in the menstrual phase compared to the early 
secretory phase of controls, whereas 242 genes were expressed differentially between 
phases in endometriosis tissue. Several important pathways were identified as being 
potentially altered including those involved in extracellular matrix remodeling, 
coagulation, and cell renewal. Of particular interest was the decrease in fibrinogen beta 
chain identified in endometriosis patients, although its potential role in the disease 
process is unclear.  
Khan et al. investigated the difference in gene expression in fertile Indian women 
with various stages of endometriosis in both the proliferative and secretory stages of the 
cycle 65. Eutopic and ectopic tissue samples were obtained from 18 women with ovarian 
endometriosis and analyzed with an expression array covering 44,000 gene products. 
They reported an increase in the number of down-regulated genes as disease stage 
became more advanced. In addition, a large number of genes were silenced in ectopic 
tissue from stage 4 endometriosis when compared to ectopic tissue from stage 3 
endometriosis. Genes involved in steroidogenesis were shown to be upregulated in 
ectopic tissue samples. A portion of genes demonstrated to be involved in immune 
response were shown to be expressed differentially in both eutopic and ectopic 
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endometrial tissue samples. In addition, differential expression of erb-b2 erythroblastic 
leukemia viral oncogene homolog 3 (ERBB3) and progesterone receptor (PGR) in both 
tissues was noted. These results suggest that both the eutopic and ectopic 
endometrium of women with endometriosis may harbor similar genetic alterations, thus 
if the eutopic endometrium from an individual with endometriosis is misplaced by way of 
retrograde menstruation or other means, it may have the potential to form 
endometriosis.    
In an attempt to gain a more clear understanding of the disease mechanisms 
involved in endometriosis, Sundqvist et al. examined the mRNA levels of 6 genes 
thought to be vital to disease progression 76. Eutopic endometrium from control 
individuals and from endometriosis patients and endometriomal biopsies were obtained 
from women in the proliferative and secretory phases of the menstrual cycle. 
Expression of ApoE, ITGB2, ITGB7, LAMC1, CD24, and JAM-1 were investigated in 
each sample. ApoE and JAM-1 were found to be down-regulated in endometrium of 
endometriosis patients in both phases examined while LAMC1 was down-regulated in 
the proliferative phase only.  ApoE has been shown to be involved in cell proliferation 
and lesion survival. CD24 was expressed differentially between the endometrium of 
endometriosis patients and endometriomas, as was ITGB2 in the endometrium of 
controls versus endometriosis patients in the secretory phase. Altered expression of 
these genes may affect cellular processes involved in the development of endometriosis 
including cellular adhesion and migration, lesion formation and survival, and immune 
response. Additionally, aberrant expression of ApoE, CD24, and JAM1 has been 
reported previously in ovarian and endometrial cancer.    
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While these studies can be informative, results can be difficult to interpret as the 
endometrium and endometriosis tissue are constantly proliferating and genes are 
expressed differentially depending on what stage of menstrual cycle the patient is in at 
the time of biopsy. Patient selection, sample size, controls, histological versus visual 
confirmation of disease tissue, sample type, and array bias are just a few of the factors 
that may explain the inconsistencies observed in the studies summarized. It should be 
noted that many of the genes reported to be aberrantly expressed in endometriosis 
have previously been shown to be differentially expressed in various cancers including 
ovarian cancer. In addition, mRNA levels of genes involved in many processes thought 
to be vital to the development and progression of endometriosis were shown to be 
expressed differentially in disease patients including those involved in immune 
response, cell cycle control, inflammation, DNA repair, cellular adhesion and 
attachment, cell proliferation and survival, and tumor suppression.   
Summary 
Many studies have been done to attempt to identify genes involved in the 
pathogenesis of endometriosis. As our knowledge on the genetics of the disease 
expands, the biological mechanisms will become more apparent. The literature thus far 
supports the hypothesis of a genetic component to the disease and also suggests a link 
to cancer as most implicate the loss of tumor suppressor genes or alterations in genes 
known to be associated with various cancers. This correlation to malignancy may be 
clinically important as endometriosis is thought to be a benign disease despite the fact 
that research may imply it to be a precursor to cancer.  
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CHAPTER 3 
PROJECT SUMMARY 
Significance of Research 
The Endometriosis Association estimates that 5.5 million women and girls in 
North America alone suffer from endometriosis, although the exact number is difficult to 
calculate as some women are asymptomatic or fail to seek medical treatment.  The 
reality is that the actual number of those with the disease may be much higher. Little 
has been established regarding the pathophysiology of endometriosis. The lack of 
findings in this area may be due to small numbers of participants, to the novelty of the 
technology, to high cost of methods, or to a combination of these factors. An attempt at 
the initiation of an endometriosis cell line to be submitted to the NIH repository will be 
made in order to facilitate future research endeavors. This is a vital part in furthering 
research as there are currently no cell lines of this kind available in the United States. 
As this is a unique area of research, negative findings would also be valuable as ruling 
out chromosomal aberrations would allow investigators to eliminate this as a probable 
cause and look into other potentially productive areas.  By using a variety of tests and 
keeping in mind existing research, we are hoping to find a definitive answer to whether 
or not chromosomal imbalances are involved in the development or progression of 
endometriosis. A finding in this area would provide insight into the disease mechanism 
and may aid in the development of future treatments and diagnostic tools. 
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Research Goals 
• Collect and analyze 20 blood samples from endometriosis patients using the 
105K oligo-CGH platform. 
• Collect and analyze 10 endometriosis tissue samples using the 105K oligo-CGH 
platform. 
• Analyze 10 samples for regions of loss of heterozygosity using the 180K oligo-
CGH microarray platform. 
• Initiate endometriosis cell lines and submit to a repository for use in future 
research.  
• Send samples for targeted sequencing to confirm copy number variants. 
 
Statement of Research 
The goal of this research is to determine if common chromosomal aberrations in 
the form of additions, deletions, or regions of loss of heterozygosity are present in a 
population of endometriosis patients that may contribute to the establishment or 
progression of the disease. 
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CHAPTER 4 
MATERIALS AND METHODS 
Patient Selection and Control Individuals 
Approval for this study was obtained from the Institutional Review Board of East 
Tennessee State University (IRB#0311.4s, IRB#0511.3) as well as the Mountain States 
Health Alliance Research Department (MSHA Protocol # 2011-027NB). Informed 
consent was given by each of the participants prior to the study. For the portion of the 
study in which blood samples were drawn for microarray analysis, all patients 
diagnosed with endometriosis by the attending physician were eligible for participation 
regardless of age or stage of disease. Control participants were eligible for participation 
if they were over the age of 30 with no history of endometriosis, no family history of 
endometriosis, and no history of infertility as evidenced by having 2 or more children. 
One individual, age 24, did not meet all of the criteria but was included as she had 
undergone multiple examinations without diagnosis of the disease. Even with these 
criteria, any of the control individuals could potentially have endometriosis because, as 
stated, many women are asymptomatic. For the portion of the study in which tissue 
biopsies were collected for microarray analysis, all patients diagnosed with 
endometriosis by laparoscopy were eligible for participation regardless of age or stage 
of disease. Only biopsies that were confirmed positive for endometriosis by Dr. Norman 
Assad and Watauga Pathology, Board Certified Pathologists were analyzed and 
included in the study.  
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 Participant Privacy 
Researchers had no immediate access to patient records. Each patient sample 
was assigned a numerical label at the clinic at the time of collection, and the sample 
was stripped of all patient identifiers. In the event a patient needed to be contacted in 
regards to a sample, the attending physician was notified and given the associated 
numerical label and was able to identify the patient. Informed consent forms were kept 
in a locked cabinet at the participating clinic. All patient results were saved with 
numerical labels on a study database at East Tennessee State University in Stanton 
Gerber Hall, Lab 124A. This database was password protected and the lab was locked 
any time study personnel were not present. 
 
 Sample Collection 
Whole blood was collected from patients with visually confirmed endometriosis of 
various stages of severity by laparoscopic examination at the participating clinic. 
Approximately 5 mL of blood was obtained by venipuncture and stored in a sodium 
heparin tube at 4° until DNA extraction.  The endometriosis patients ranged in age from 
24 to 44 years with a mean age of 32.4±5.5. The age of control individuals ranged from 
24 to 64 years with a mean age of 46.9±12.9. 
Tissue samples were collected from endometriosis patients who were 
undergoing laparoscopic surgery for treatment of the disease. Biopsies were placed in a 
sterile container by the physician with approximately 20 mL of Hank’s Balanced Salt 
Solution (Life Technologies) at 4° until they were to be processed. Samples were 
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included in the study after they were confirmed positive for endometriosis by visual 
inspection by the operating physician and by histological examination from Watauga 
Pathology, Board Certified Pathologists. Controls for the tissue samples consisted of 
blood matches from the same patient which allowed investigators to compare the 
tissues and look for variation between them.  
 Microarray Preparation and Analysis 
 The summary of the microarray workflow is depicted in Figure 7. 
Figure 7 Microarray Workflow: Peripheral blood or tissue samples are obtained from 
the participating clinic. DNA is extracted from the sample followed by DNA purification. 
A restriction enzyme digest is performed, and fragment size is checked using the 
Agilent Bioanalyzer. DNA samples are fluorescently labeled and hybridized to 
microarray slides. The slides are scanned and analyzed using BlueFuse software.  
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DNA Extraction from Peripheral Blood 
Genomic DNA was extracted from 200 µ whole blood with the QIAamp DNA 
Blood Mini Kit (Qiagen). Proteinase K (20µ, 45 mAU/mg protein) was added to whole 
blood in a 1.5 mL tube followed by RNase A (4µ, 100mg/ml). Samples were vortexed 
briefly, centrifuged, and allowed to incubate for 2 minutes at room temperature. Lysis 
Buffer was added (200µ) and samples were vortexed for 15 seconds, centrifuged, and 
incubated for 10 minutes at 56°C. Ethanol was added (200µ, 96%-100%) and samples 
were vortexed for 15 seconds, centrifuged, and added to a QIAamp Mini spin column. 
Samples were centrifuged for 1 minute at 8,000 rpm. Columns were washed with a 
series of wash buffers and dried by centrifugation for 1 minute at 14,000 rpm. Tris-
EDTA (200µ, Fluka) was applied to the column and allowed to incubate at room 
temperature for 5 minutes. DNA was eluted by centrifuging columns for 1 minute at 
8,000. DNA purity and concentration was measured using the Nanodrop 2000 
Spectrophotometer (Thermo Fisher Scientific). 
 
DNA Extraction from Tissue Biopsy 
Genomic DNA was extracted from approximately 25mg of endometriosis tissue 
with the QIAamp DNA Mini Kit (Qiagen). Each biopsy was removed from its sterile 
container and put in a 35x10mm petri dish with Tissue Lysis Buffer (180µ). Biopsies 
were photographed (Figure 8) and minced using sterile instruments prior to DNA 
extraction. The mixture was added to a 1.5 mL tube with Proteinase K (20µ) and 
incubated for up to 24 hours at 56°C to allow lysis to occur, vortexing often. RNase A 
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(20µ, 100mg/ml) was added and allowed to incubate for 2 minutes at room temperature.  
Samples were vortexed briefly, centrifuged, and allowed to sit for 2 minutes at room 
temperature. Lysis Buffer was added (200µ) and samples were vortexed for 15 
seconds, centrifuged, and incubated for 10 minutes at 56°C. Ethanol was added (200µ, 
96-100%) and samples were vortexed for 15 seconds, centrifuged, and added to a 
QIAamp Mini spin column. Samples were centrifuged for 1 minute at 8,000 rpm. 
Columns were washed with a series of wash buffers and dried by centrifugation for 1 
minute at 14,000 rpm. Tris-EDTA (200µ, Fluka) was applied to the column and allowed 
to incubate at room temperature for 5 minutes. DNA was eluted by centrifuging columns 
for 1 minute at 8,000 rpm. DNA purity and concentration was measured using the 
Nanodrop 2000 Spectrophotometer (Thermo Fisher Scientific) 
 
Figure 8 Endometriosis tissue biopsies: Biopsy size and appearance varied 
depending on location, severity of disease, and stage of the menstrual cycle in which 
they were collected. Typical indications of necrotic tissue were noted as bubbles or 
blebbing under 10x magnification in type II and type III biopsies  (A) Type I biopsy: 
Unpigmented tissue generally has a smooth appearance and is associated with early 
stages of disease and/or menstrual cycle stage and contain mainly living cells (B, 
C)Type I biopsy under 10x magnification. Tissue appears to be made up of living cells 
with no necrotic blebbing (D) Type II biopsy: Unpigmented biopsy with dark, pigmented 
regions generally has a smooth appearance with necrotic blebbing.  This type of biopsy 
is associated with moderate stages of disease and/or menstrual cycle stage and 
contains a mixture of living cells and necrotic cells (E,F) Type II biopsy under 10x 
magnification. Tissue appears to be composed of a mixture of living cells and necrotic 
bubbles (G) Type III biopsy: Dark pink to red in color with hemosiderin deposits 
throughout with a necrotic appearance and generally associated with moderate to late 
stages of disease and/or menstrual cycle stage containing mainly necrotic cells (H, I) 
Type III biopsy under 10x magnification. Tissue appears to be composed of mainly 
necrotic bubbles 
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Figure 8 continued 
A.     B.    C.  
D.     E.     F.  
G.     H.      I.                                                                        
 
DNA Purification 
DNA was purified with the Wizard Clean-up Kit (Promega). DNA in approximately 
200µ of Tris-EDTA (Fluka) was added to DNA Clean-Up Resin (1 mL) and mixed by 
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inversion. A minicolumn was attached to a syringe barrel and the mixture was applied. A 
vacuum was applied to draw the solution through the minicolumn where the DNA 
remained bound. The vacuum was broken. Isopropanol (2 mL, 80%) was added to each 
sample and drawn through the minicolumn into a reservoir where it was discarded after 
an additional 20 seconds of drying. The minicolumn was centrifuged at 14,000 rpm for 2 
minutes to prevent carryover of isopropanol. Prewarmed Tris-EDTA (50µ, 65-70°C) was 
added to the column and allowed to incubate at room temperature for 1 minute before 
elution by centrifugation for 30 seconds at 14,000 rpm. DNA purity and concentration 
was measured using the Nanodrop 2000 Spectrophotometer. 
 
DNA Digestion 
Normal female control DNA was purchased from Promega (Madison, Wisconsin). 
A concentration of approximately 0.075 ug/ul of each DNA sample was obtained, and a 
restriction digestion was performed on each by adding endonucleases Alu I (10U/ul) 
and Rsa I (10U/µ) (Promega) to purified DNA and acetylated bovine serum albumin 
(10mg/ml, Promega). The restriction enzyme recognition sites are provided below. 
Alu I:    Rsa I: 
5’…AG^CT…3’   5’…GT^AC…3’ 
                               3’…TC^GA…5’           3’…CA^TG…5’ 
  The mixture was incubated at 37°C for 2 hours followed by incubation at 65°C for 10 
minutes.  Successful digestion was assessed using the Agilent 2100 Bioanalyzer 
(Agilent Technologies-Santa Clara, California). A gel matrix containing DMSO was 
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prepared by adding 15µ of fluorescent dye to the gel. The mixture was added to a spin 
column and spun at 6,000 rpm for 10 minutes and stored protected from light at 4°C. A 
DNA1000 chip (Agilent Technologies) was placed on a priming station and 9µ of gel 
matrix was added to the appropriate well. The chip was pressurized and the gel matrix 
was spread by depressing the plunger on the priming station for 60 seconds before 
releasing. A DNA ladder (Agilent Technologies) was added to the appropriate well. 
Upper and lower markers, 1,500 and 15 base pairs in length were added to each well 
followed by 1µ of each sample to be analyzed. The loaded chip was vortexed at 2,400 
rpm for 60 seconds, placed in the Agilent Bioanalyzer, and analyzed using 2100 Expert 
software (Agilent Technologies).  A successful digestion was evident when the majority 
of fragments were between 200 and 600 base pairs in length (Figure 9).  As each lane 
was read, information was provided as to the concentration and size of DNA fragments 
detected. 
Figure 9 Agilent Bioanalyzer Output:  Successful digestion is indicated by a smear 
pattern (lanes 1-4) as well as clean “blank” lanes (lane 5). 
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Enzymatic Labeling 
  Sample DNA and control DNA were labeled with Cy3 and Cy5 fluorophores 
(dUTP/oligo, Bluegnome, Cambridge, UK). Random primers were added to each 
sample, and all were incubated at 95°C for 5 minutes followed by incubation at 4°C for 5 
minutes. Klenow fragment of DNA Polymerase I and 10xdNTP were added followed by 
dUTP-Cy3 to the sample DNA and dUTP-Cy5 to the control DNA. Samples were 
transferred to a thermocycler and incubated at 37°C for 2 hours followed by incubation 
at 65°C for 10 minutes. Excess label was removed from each sample by washing with 
Tris-EDTA buffer solution (pH 7.4, Sigma) and filtering using Amicon Ultracel-30K 
membrane filters (EMD Millipore). DNA yield, purity, and dye incorporation were 
measured for each sample using the Nanodrop 2000 Spectrophotometer (Thermo 
Fisher Scientific- Waltham, Massachusetts). Each patient sample was combined with its 
corresponding control and stored protected from light at 4°C until further processing.  
 
Microarray Hybridization and Data Analysis 
Hi-RPM-2x hybridization buffer and blocking agents including human COT DNA 
(1.0 mg/ml, Invitrogen) were added to the labeled DNA to minimize the binding of 
repetitive sequences. The solution was incubated at 95°C for 3 minutes followed by 
incubation at 37°C for 30 minutes then cooled to room temperature. The solution was 
dispensed onto a gasket slide and microarray slides (CytoChip Oligo 2x105K or 
Cytochip SNP 4X180K: Bluegnome) were placed. Slides were incubated in hybridization 
chambers at 65°C for 24 (Cytochip Oligo 4x180K) or 40 hours (Cytochip 2x105K). The 
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hybridization chambers were disassembled in Agilent Oligo aCGH/ChIP-on-Chip Wash 
buffer 1 (Agilent Technologies) and washed for 5 minutes. The slides were transferred 
to a 37°C bath of Agilent Oligo aCGH/ChIP-on Chip Wash buffer 2 (Agilent 
Technologies) for 1 minute and then allowed to air dry.  
Microarray slides were scanned using a GenePix 4000B scanner (Molecular 
Devices) and an image was created using GenePix software (Figure 10). The images 
were analyzed with BlueFuse Multi software (Bluegnome) and information on any copy 
number variants was provided including size, location, possible affected genes, known 
pathogenesis, and relevant publications (Figures 11 and 12). Each copy number variant 
(CNV) was investigated further using the Ensembl, Online Mendelian Inheritance in Man 
(OMIM), and UCSC Genome Bioinformatics browsers.  
   Two microarray platforms were used in this study. The Cytochip 2x105K platform 
includes105,000 probes while the Cytochip SNP 4x180K platform includes 180,000 
probes spanning the genome at approximately every 30,000 base pairs but at higher 
densities in disease prone regions. Both platforms identify copy number variants, 
however, the Cytochip SNP 4x180K platform has an additional 27,000 probes for single 
nucleotide polymorphisms which allow for the identification of regions of LOH. The 
BlueFuse Multi software is designed with an algorithm that recognizes variations in 
hybridization by identifying differences in fluorescence between the patient and the 
control DNA and flagging those that are within array parameters set by the user. Array 
parameters for the current study were set to zero base pairs so as not to eliminate any 
additions or deletions based on size allowing for the most detailed analysis possible. An 
example of the output for a patient with trisomy X is shown below (Figures 13 and 14) 
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and has been flagged as such. The Database of Genomic Variants 77 was used to 
eliminate any known copy number variants from the results.  
Figure 10 GenePix 4000B Scanner Raw Image: Equal hybridization of both patient 
and control DNA indicated by yellow spots while control spots with no hybridization of 
DNA are indicated by blank spots  A. Cytochip Oligo 2x105K scan B. Cytochip SNP 
4x180K scan C. Increased hybridization of patient DNA representative of a gain 
indicated by green spot and green arrow D. Decreased hybridization of patient DNA 
representative of a deletion indicated by a red spot and red arrow. 
      A.      B.     C.    D.  
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Figure 11 BlueFuse Multi Software Output, CGH View: Copy number variants are 
identified and information regarding known pathogenicity, size, and location is 
provided.  
 
 
Figure 12 BlueFuse Multi Software Output, Decision Tracks View: Trisomy X is 
indicated by the flagging of the X chromosome in green in the “Current” output. 
Information is provided on previous publications including the area of interest. Genes 
located in the region are listed as well as diseases previously reported to be associated 
with the loss or gain of the gene. Available probes for FISH studies are also listed for 
follow-up confirmation.  
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Figure 13 BlueFuse Multi Software Output, Karyotype View: Additions are 
flagged in green to the right of the chromosome (chromosome 15, 17, X and Y) and 
deletions are flagged in red to the left of the chromosome (chromosome 10). The 
presence of an extra X chromosome, trisomy X (47, XXX) is indicated. The Y 
chromosome shows a gain which is the result of homologous DNA sequences on 
the X and Y chromosomes. This observation is a common occurance in nearly all 
samples analyzed.                 
 
 
Figure 14 BlueFuse Multi Software Output, Chromosome View: (A) A normal female 
(46, XX) indicated by the majority of probes  for the X chromosome inside the standard 
deviation limits indicated by the left red line and the right green line. (B) A trisomy X 
female (47, XXX) indicated by the majority of probes being skewed to the right, outside 
of the standard deviation limits.                                                         
A.        B.  
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 Cell Line Preparation 
Cell Culture 
Tissue biopsies were obtained as previously described and placed in a sterile 
container with approximately 20ml of Hank’s Balanced Salt Solution (Life Technologies). 
Biopsies were stored at 4°C until cultures were set up. Aseptic technique was used in all 
aspects of cell culture preparation. Amniomax media (8ml: Gibco, Life Technologies) 
was added to the appropriate number of culture flasks based on biopsy size and 
number. Biopsies were placed in 35x10mm petri dishes, diced, suspended in culture 
media (4ml, Amniomax-II Complete: Life Technologies), and divided into the appropriate 
number of culture flasks. Flasks were incubated at 37°C, 7.5% CO2, and 75% humidity 
until the cultures reached approximately 75% confluency at which time cells were either 
subcultured, harvested, or cryopreserved. 
 
Cell Subculture 
Culture media from each flask was poured off and discarded. To remove any 
serum present in the culture and to aid in releasing cells trypsin was added (4ml, 0.05% 
Trypsin EDTA (1X): Life Technologies) and was immediately poured off. Three 
additional milliliters of trypsin was added and the flasks were incubated for 4 minutes at 
37°C. Cultures were observed under magnification to ensure the majority of cells were 
released from the flask. Culture media (12ml, Amniomax-II Complete: Life 
Technologies) was added, and cells were suspended by pipetting. The mixture was 
removed from the original flask and divided into the appropriate number of new sterile 
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flasks. Additional culture media was added to each flask to bring the volume to 
approximately 10ml.  Cultures were returned to the incubator with the temperature 
maintained at 37°C.  
 
Cell Line Cryopreservation 
Cells were released from the culture flask using trypsin as described above. The 
suspended cells were dispensed into 15ml conical tubes and pelleted by centrifugation 
for 4 minutes at 1000 rpm. The supernatant was discarded, and freezing media (1ml, 
Cell Freezing Medium –DMSO (1X): Sigma Aldrich) was added to each cell pellet 
dropwise and mixed by pipetting. Cells were aliquoted into cryopreservation vials and 
placed in a freezing container at -80°C for approximately 24 hours where cells were 
cooled by 1°C per minute.  Vials were then transferred to liquid nitrogen for long-term 
storage.  
 
Cell Harvest 
When cells reached approximately 75% confluency, colcemid (0.2ml, Karyomax: 
Life Technologies) was added to each culture flask and incubated for 3-4 hours at 37°C. 
Culture media was poured off into 15ml conical tubes. Trypsin was added (4ml) and 
immediately poured off followed by the addition of 3ml of trypsin. Flasks were incubated 
for 4 minutes at 37°C. Each culture was checked under magnification for the release of 
the cells from the flask. Hank’s Balanced Salt Solution (12ml: Life Technologies) was 
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added to each culture and the cell mixture was poured into a 15ml conical tube. After 
centrifugation for 4 minutes at 1000 rpm, the supernatant was removed leaving a cell 
pellet. After vortexing briefly, the cells were incubated in a hypotonic solution (10 ml: 
NaCl) for 15 minutes at room temperature. The cells were centrifuged for 4 minutes at 
1000 rpm, the supernatant was removed, and the pellet was vortexed briefly. The cells 
were then washed in a fixative solution (10ml, 75% methanol, 25% glacial acetic acid) 
and centrifuged for 4 minutes at 1000 rpm. Washing was repeated 3-4 times. The cells 
were then stored in fixative solution at room temperature until use.  
 
Karyotype Analysis 
Slide Preparation 
Harvested cells the tubes were centrifuged for 4 minutes at 1000 rpm, and the 
supernatant was removed. Fresh fixative solution (0.25-0.5 ml) was added to each 
pellet, and the pellet was disrupted with the tip of a glass pipet. Cells were aspirated 
and dropped onto slides wetted in chilled, distilled water. Slides were dried on a damp 
paper towel on a slide warmer and then baked in an 85-90°C oven for 2-24 hours before 
staining.  
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Slide Staining 
A series of coplin jars were prepared containing the following: 
1. 50ml 0.9% NaCl+2.5ml Trypsin  (Life Technolgies) 
2. 50ml 0.9% NaCl 
3. 50ml 0.9% NaCl 
4. 49ml Gurr’s buffer + 3ml Giemsa stain (KaryoMax, Life Technologies) + 1ml 
Acetone 
5. 50ml Gurr’s buffer 
6. 50ml Gurr’s buffer 
Slides were dipped briefly in jars 1, 2, and 3 and in jar 4 for 2-4 minutes. Slides were 
rinsed through jars 5 and 6 for several seconds and allowed to dry on a slide warmer 
before viewing with oil immersion microscopy.  
 
Karyotyping 
Chromosome spreads were visualized and ideal spreads with clear banding and 
few overlaps were photographed (Figure 15). Images were manipulated in Adobe 
Photoshop and printed for karyotyping. Each chromosome was cut out and positioned 
according to size and banding pattern on a karyotype sheet (Figure 16). 
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Figure 15 Ideal chromosome spread  
 
67 
 
Figure 16 Complete Karyotype 
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CHAPTER 5 
RESULTS 
CGH Microarray: 105K Platform 
Peripheral Blood Samples  
 Genomic DNA from the peripheral blood of 32 endometriosis patients and 20 
control individuals was analyzed by oligo-comparative genomic hybridization for 
chromosomal imbalances. All patients included in the study were confirmed as having 
the disease by laparoscopy performed by Dr. Norman Assad. Array data were analyzed 
using BlueFuse Multi software. The array parameters were set with no minimum 
deletion or addition size so as not to eliminate any copy number variants on the basis of 
size alone. All CNVs reported were initially considered as potential pathogenic markers 
and were entered into a spreadsheet to track any recurring CNVs in each group. The 
Database for Genomic Variants 77 was used to eliminate common polymorphisms. After 
common polymorphisms were eliminated, CNVs that appeared at a higher frequency in 
the patient group than the control group were analyzed for their potential to contributing 
to the pathogenesis of endometriosis.  
Copy number variants of various sizes and in multiple locations were detected in 
30 of 32 endometriosis patients and in 18 of 20 control individuals. A total of 125 
different copy number variants were reported including 63 losses and 62 additions. 
Losses were detected on all chromosomes except for chromosome 13. Gains were 
detected on all chromosomes except for chromosomes 18, 20, and 21. The mean 
number of copy number variants detected in the DNA from endometriosis patients was 
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5.6±3.2 and a range from 0 to 12. The mean number of additions was 3.0 and the mean 
number of deletions was 2.6. Control individuals had a mean of 6.7±3.8 with a range 
from 0 to 14. The mean number of additions detected was 3.3 and the mean number of 
deletions was 3.4. This information is summarized in Table 4.  
Table 4 Copy number variant results from peripheral blood samples 
 Endometriosis Patients Controls 
Minimum/Maximum CNVs 0/12 0/14 
Mean number of gains 3.0 3.3 
Mean number of losses 2.6 3.4 
Mean of total CNVs 5.6 6.7 
 
 
Chromosome 17p13.3 Addition in Peripheral Bloods: HIC-1 
Analysis of the microarray data indicated the presence of one potentially 
significant addition on chromosome 17. This addition was the only copy number variant 
reported at a higher frequency in the patient group than the control group.  The addition 
ranged in size from 39 to 624 base pairs on 17p13.3 in 75% of endometriosis patients 
but only 50% of control individuals. The additions had varying start positions depending 
on the CNV size, but all had the same end position at 17:1,959,650. The addition is 
located in the hypermethylated in cancer-1 gene (HIC-1). The microarray data from the 
blood samples are shown below in Tables 5 and 6. 
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Table 5 Microarray results (105K) of DNA isolated from the peripheral blood from 
endometriosis patients. 
Peripheral Blood Samples from Endometriosis Patients: 105K Platform 
Patient 
ID 
Age Disease Stage Number of CNVs Additions  Deletions 17p Addition? Addition Size 
(base pairs) 
1005 35 I-II 8 3 5 No 0 
1008 26 I-II 2 2 0 Yes 57 
1009 38 III-IV 4 2 2 Yes 77 
1010 35 III-IV 6 1 5 No 0 
1011 44 I-II 8 4 4 Yes 39 
1012 30 III-IV 5 3 2 Yes 77 
1013 32 I-II 1 0 1 No 0 
1015 35 III-IV 5 3 2 Yes  77 
1016 34 III-IV 12 1 11 Yes 77 
1017 25 I-II 8 5 3 Yes 39 
1018 33 I-II 11 9 2 Yes 77 
1019 44 III-IV 9 7 2 Yes 121 
1020 34 I-II 11 5 6 Yes 121 
1021 30 I-II 5 4 1 Yes 121 
1022 33 III-IV 8 3 5 Yes 77 
1023 28 Unspecified 5 2 3 Yes 39 
1026 33 Unspecified 7 4 3 Yes 121 
1028 34 Unspecified 8 4 4 Yes 77 
1029 31 III-IV 0 0 0 No 0 
1030 28 I-II 5 4 1 Yes 77 
1031 24 I-II 8 3 5 Yes 121 
1033 32 I-II 5 1 4 yes  39 
1034 27 I-II 3 2 1 No 0 
1036 44 I-II 0 0 0 No 0 
1039 24 I-II 1 1 0 Yes 624 
1050 31 I-II 5 1 4 No 0 
1051 29 I-II 3 3 0 Yes 77 
1056 37 I-II 3 2 1 No 0 
1059 27 III-IV 9 4 5 Yes 39 
1060 28 I-II 3 3 0 Yes 77 
1063 31 I-II 4 3 1 Yes 77 
1064 40 I-II 8 8 0 Yes 77 
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Table 6 Microarray results (105K) of DNA isolated from the peripheral blood from 
control individuals 
Peripheral Blood Samples from Control Individuals: 105K Platform 
Patient ID Age Number of 
CNVs 
Additions Deletions 17p Addition? Addition Size 
(base pairs) 
0001 24 1 1 0 No 0 
0003 64 5 3 2 Yes 39 
0004 50 9 6 9 Yes 39 
0005 57 6 3 3 No 0 
0006 56 3 2 1 No 0 
0007 44 6 1 5 No 0 
0008 58 5 3 2 No 0 
0009 30 7 3 4 No 0 
0010 43 16 9 6 No 0 
0011 35 5 2 3 Yes 121 
0012 35 4 2 2 Yes 39 
0013 31 5 4 1 Yes 77 
0014 53 10 4 6 Yes 39 
0015 60 2 2 0 No 0 
0016 61 13 1 12 No 0 
0017 64 11 8 3 Yes 39 
0018 30 3 1 2 No 0 
0020 36 7 3 4 Yes 77 
0021 56 5 1 4 Yes 39 
0022 50 10 7 3 Yes 121 
 
 
Endometriosis Tissue Biopsies  
 Genomic DNA from endometriosis tissue biopsies from 10 endometriosis patients 
was analyzed by oligo-comparative genomic hybridization microarray for chromosomal 
imbalances. All patients included in this portion of the study were confirmed as having 
endometriosis by Dr. Norman Assad after laparoscopic examination and by Watauga 
Pathology, Board Certified Pathologists by histological examination. Copy number 
variants were detected in all samples. The mean number of copy number variants 
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detected was 4.1±2.3 and a range from 1 to 7. The mean number of additions was 3.2 
and the mean number of deletions was 0.9. Of the 10 tissues obtained, 4 were taken 
from the ovary and 6 were taken from the peritoneum in various locations.  Disease 
severity was reported as being mild to moderate (stage I-II) in 8 cases analyzed and 
moderate to severe (stage III-IV) in 3 cases analyzed. 
 
Chromosome 17p13.3 Addition in Tissue Biopsies: HIC-1 
Analysis of the microarray data indicated the presence of the addition on 
chromosome 17p13.3 reported previously in 100% of the DNA samples obtained from 
the endometriosis tissue biopsies. The addition was of the same size range and location 
as reported in the DNA obtained from the blood samples with a range of 39 to 624 base 
pairs and an end point of 17:1,959,650.   
The results from the tissue biopsies with their corresponding peripheral blood 
samples are included in Table 8. Only 6 of the 10 corresponding peripheral blood 
samples shared the addition on chromosome17p13.3 that was found in the tissue 
samples. The addition size was the same in the peripheral blood and tissue from 3 
subjects, larger in the blood of 2 subjects, and larger in the tissue of 1 subject (Figure 
17, Table 8). 
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Figure 17 Chromosome 17p13.3 addition size in endometriosis tissue versus 
peripheral blood 
 
 
Table 7 Microarray results (105K) of DNA isolated from endometriosis tissue 
biopsies from endometriosis patients 
Tissue Samples from Endometriosis Patients: 105K Platform 
Patient 
ID 
Age Biopsy 
Location 
Disease 
Stage 
Number 
of CNVs 
Additions Deletions 17p13.3 
Addition Size 
(base pairs) 
1029 31 Ovary III-IV 2 2 0 555  
1030 27 Ovary III-IV 6 3 3 76  
1034 28 Ovary I-II 6 4 2 56  
1036 37 Ovary I 6 5 1 39  
1039 27 Peritoneum II 1 1 0 39  
1051 40 Peritoneum II 6 4 2 76  
1056 24 Peritoneum I-II 2 2 0 624  
1059 43 Peritoneum I-II 3 3 0 120  
1060 26 Peritoneum I 2 2 0 76  
1063 29 Peritoneum I 7 6 1 76  
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Table 8 Microarray results (105K) from the DNA isolated from endometriosis 
tissue biopsies and corresponding peripheral blood samples from endometriosis 
patients 
Tissue Samples with Corresponding Peripheral Bloods from Endometriosis 
Patients: 105K Platform 
Patient ID Age Biopsy Location Disease Stage Addition Size in Tissue 
(base pairs) 
Addition Size in Blood 
(base pairs) 
1029 31 Ovary III 555  0 
1030 27 Ovary III 77  39  
1034 28 Ovary I-II 57  77  
1036 37 Ovary I 39  0 
1039 27 Peritoneum II 39  77  
1051 40 Peritoneum II 77  77  
1056 24 Peritoneum I-II 624  624  
1059 43 Peritoneum I-II 121  0 
1060 26 Peritoneum I 77  0 
1063 29 Peritoneum I 77  77  
 
 
CGH Microarray: 180K Platform 
The DNA from the endometriosis tissue biopsies was examined on an additional 
microarray platform to investigate potential regions of loss of heterozygosity as well as 
additional CNVs. This platform had a greater number of oligos in addition to 27,000 
single nucleotide polymorphisms that allow the identification of LOH. As expected, this 
platform revealed a greater total number of CNVs than the previous platform with an 
average of 10.8±7.3 CNVs and a range of 1 to 23. The average number of additions 
identified was 8.5, and the average number of deletions identified was 2.3. No additional 
CNVs were identified with this platform.  
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Eight of 10 samples displayed regions of LOH on various chromosomes including 
2, 4, 5, 6, 10, 11, 12, 13, and X chromosomes (Table 9).Only 1 common region of LOH 
was reported in 2 cases on chromosome 4q33.  
 
Table 9 Microarray results (180K) of DNA isolated from endometriosis tissue 
biopsies  
Tissue Samples from Endometriosis Patients: 180K Platform 
Patient 
ID 
Age Biopsy Location  Disease 
Stage 
Number 
of CNVs 
Additions Deletions Regions of LOH 
1029 31 Ovary III 6 6 0 2: Chr5q23, 
Chr11q14 
1030 27 Ovary III 17 16 1 2: Chr4q33, 
Chr12p12 
1034 28 Ovary I-II 1 0 1 3: Chr2q24, 
ChrXp11, 
ChrXp21 
1036 37 Ovary I-II 10 8 2 1: Chr10q21 
1039 27 Peritoneum I-II 23 21 2 1: Chr11p12 
1051 40 Peritoneum I-II 2 2 0 0 
1056 24 Peritoneum I-II 4 2 2 0 
1059 43 Peritoneum I-II 17 10 7 1: Chr13q22 
1060 26 Peritoneum I-II 14 9 5 1: Chr4q33 
1063 29 Peritoneum I-II 14 11 3 1: Chr6p23 
  
Copy Number Variant Size Analysis 
 Microarray platforms used by other researchers to this point have been relatively 
low resolution and generally not programmed to identify CNVs under 200,000 base 
pairs in length. To identify what percentage of CNVs we were able to pick up that were 
smaller than 200,000 base pairs, all of the CNVs from the 62 samples run on the 105K 
platform were collected and graphed.  A total of 354 CNVs were identified with a mean 
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size of 300,632±625,329 and a range from 14 to 5,237,976 base pairs. The majority of 
CNVs reported are considered microadditions or microdeletions with 76% of them less 
than 200,000 base pairs in length (Table 10, Figure 18).  A total of 114 CNVs from 10 
samples run on the 180K platform were also graphed. The mean size detected was 
790,839±227,534,853 with range from 163 to 2,231,000,700. Fifty-four percent of the 
CNVs reported were less than 200,000 base pairs in length (Table 11, Figure 19).  
 
Table 10 Total CNVs by size as detected by the 105K platform 
Total CNVs: 105K Platform 
Number of Base Pairs CNV Number Percent 
1-1,000 69 19% 
1,001-5,000 3 1% 
5,001-10,000 0 0% 
10,001-50,000 20 6% 
50,001-100,000 106 30% 
100,001-199,999 71 20% 
200,000-500,000 39 11% 
500,001-1,000,000 11 3% 
1,000,001-2,000,000 17 5% 
2,000,000+ 18 5% 
Total: 354 100% 
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Figure 18 Total CNVs by percentage as detected by the 105K platform 
 
 
Table 11 Total CNVs by size as detected by the 180K platform 
Total CNVs: 180K Platform 
Number of Base Pairs CNV Number Percent 
1-1000 3 3% 
1001-5,000 6 5% 
5001-10,000 2 2% 
10,001-50,000 14 12% 
50,001-100,000 17 15% 
100,001-199,999 19 17% 
200,000-500,000 17 15% 
500,000-1,000,000 17 15% 
1,000,001-2,000,000 5 4% 
200,000,000+ 14 12% 
Total: 114 100% 
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Figure 19 Total CNVs by percentage as detected by the 180K platform 
 
 
Cell Culture 
Cell culture of endometriosis tissue is problematic as biopsy size obtained from 
laparoscopic surgery paired with ablation treatment is generally very small and 
depending on the location or stage of disease, few viable cells are present. Ten tissues 
pathologically confirmed for endometriosis were obtained for study, and 2 were 
successfully cultured including biopsies from patients 1029 and 1051. Biopsy 1029 was 
taken from the ovary of a patient with advanced stage III-IV endometriosis, and biopsy 
1051 was taken from peritoneum of a patient with moderate stage I-II of the disease. 
The cultured cells had consistent morphology and no indications of senescence. Culture 
media was changed approximately every 48 hours and subcultured when each neared 
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confluency. Routine observation of the primary cultures revealed that the majority of 
metaphase cells (approximately 90%) were unusually large potentially indicating 
polyploid cells (Figure 20). To further investigate this possibility, cultures were harvested 
for karyotyping.  
Figure 20 Endometriosis cell culture: Cells from an endometriosis tissue biopsy 
obtained from endometriosis patient number 1029. Green arrows indicate normal 
metaphase cells while red arrows indicate enlarged, potentially polyploid cells. 
      
 
Karyotyping 
Cultured cells from patient number 1029 were split 6 times prior to being 
harvested. Slides were prepared, and G-banding of the chromosomes was done for 
karyotyping. Of 100 cells visualized and counted, 76 were diploid (46,XX) and 24 were 
tetraploid (92,XXXX) as shown in Figure 21. It is difficult to obtain pure endometriosis 
cells in culture as often a portion of each biopsy contains a mixture of  cells from both 
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disease and nondisease tissue.  For this reason, karyotyping can result in a normal 
46,XX result even if the pure endometriosis cells are tetraploid. It is also possible that 
the endometriosis cells are evolving from diploid 46,XX to tetraploid, 92,XXXX which 
may yield similar results. 
Figure 21 Tetraploid karyotype: Obtained from harvested metaphase cells in cell 
culture 1029 
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CHAPTER 6 
DISCUSSION 
To our knowledge, this study was the first to examine the presence of 
chromosomal imbalances in the form of microadditions, microdeletions, or regions of 
loss of heterozygosity in the DNA from endometriosis tissue with the corresponding 
peripheral blood from the same patients using oligonucleotide based array comparative 
genomic hybridization. The results suggest that copy number variants may play a role in 
the establishment and progression of the disease as hypothesized.  
Currently, there is no biomarker for endometriosis and making visual confirmation 
by way of laparoscopy followed by histological confirmation is the accepted method for 
diagnosis. In this study we have identified an addition on chromosome 17p13.3 present 
in the blood and tissue from endometriosis patients that may serve as a genetic marker 
for the disease allowing for the development of a less invasive option for diagnosis as 
well as target for the development of a new therapeutic option.  
 
Hypermethylated in Cancer-1 
The addition located on chromosome 17p13.3 is located within the gene 
hypermethylated in cancer-1 (HIC-1). HIC-1 is expressed throughout the body but at the 
highest concentrations in the lung, colon, prostate, thymus, testis, and ovaries. It is a 
tumor suppressor gene that, as the name implies, has been shown to be 
hypermethylated in cancer as well as many precancerous tissues. This epigenetic 
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modification results in the down-regulation of gene expression by blocking the binding of 
transcription factors to the DNA and by modifying chromatin structure by way of methyl-
binding domain proteins 78. The HIC-1 gene and its function have been shown to be 
altered in cancer by various mechanisms including hypermethylation of the promoter 
region of the gene but also by deletion of the gene or regions of the chromosome 
containing the gene and losses of heterozygosity. These alterations often result in a 
reduction in gene expression or total gene silencing that may result in uncontrolled cell 
growth, tumor formation, and the development of certain cancers.  
A lack of or a decrease in HIC-1 expression associated with hypermethylation of 
the promoter region of the gene has been identified  in lung squamous cell carcinoma 
and lung adenocarcinoma 79, head and neck squamous cell carcinoma 80, 
choriocarcinoma 81, ependymomas 82, medulloblastomas 83,  breast cancer 84, prostate 
cancer 85, 86, cervical cancer 87, gastric cancer 88,  hepatocellular cancer 89, and colorectal 
cancer 90. As methylation is an epigenetic modification that may occupy the DNA at 
varying densities, gene expression may be altered to different degrees from a reduction 
to a total lack of gene expression. Identification of “hemi-methylated” regions in the 
normal tissue when compared to dense hypermethylation in cancer tissue may indicate 
that the degree of methylation of one or both alleles may be directly correlated to gene 
expression thus the severity or presence of disease 84, 91. Hypermethlyation has also 
been shown to occur in various precancerous tissues 81, 85, 88, 89 which strengthens the 
notion that methylation may play a role in disease development and progression. In 
other words, patients with one hypermethylated allele may be predisposed to 
developing cancer if and when the other allele becomes either hypermethylated or 
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inactivated by other means.  Administration of demethylating drugs has been shown to 
restore HIC-1 expression and function in some disease patients 80, 90, 92 and may be an 
option for endometriosis therapy if future studies support our findings.  
Reduced expression of HIC-1 by mechanisms other than promoter    
hypermethylation has also been reported. Deletions of all or part of chromosome 17 
containing the HIC-1 gene have been shown to occur in a variety of cancers including 
acute myeloid leukemia cell lines 93, mantle cell lymphomas 94, medulloblastomas 91, 
ovarian cancer 95, and esophageal cancer 96. Regions of LOH associated with the HIC-1 
gene have been detected in breast cancer 84, 92, gastric cancer 88, 97, hepatocellular 
cancer 89, ovarian cancer 95, esophageal cancer 96, ependymomas 82, and 
medulloblastomas 91. It has been suggested that these alterations are related as LOH 
has been thought to be a potential consequence of DNA hypermethylation. This post 
translational modification may make chromatin more susceptible to structural changes 
resulting in loss of heterozygosity and a reduction or loss in gene function 98. In either 
case, the loss of function of HIC-1 function contributes to tumor formation and possibly 
cancer development.  
Changes in the HIC-1 gene may play a role in the development of disease, but it 
is also located just upstream and downstream of other potentially pathogenic genes100. 
HIC-1 resides approximately 13,000 base pairs from the ovarian cancer tumor 
suppressor gene (OVCA2) that has been demonstrated to be aberrantly expressed in 
ovarian cancer 99 and approximately 10,000 base pairs from diphthamide biosynthesis 
protein 1 (DPH1) that is a tumor suppressor involved in cell cycle control in ovarian 
cells.  Patients with endometriosis have an increased chance of developing ovarian 
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cancer, and the distinction between the 2 diseases becomes progressively unclear as 
we continually reveal similarities between them. It has yet to be elucidated if a mutation 
in HIC-1 gene could be affecting either OVCA2 or DPH1 therefore contributing to 
disease state. Other genes in the vicinity of HIC-1 include nonsense mediated mRNA 
decay factor (SMG8) that is involved in eliminating premature stop codons, CTD-
254H1.2 which is associated with the abnormal growth of blood vessels in the eye in 
Coates disease, and retinitis pigmentosa (RP11), which is associated with a 
degenerative disease of the eye.  
It is unclear at this point how the addition of a portion of HIC-1 may play a role in 
the pathogenesis of endometriosis. The addition may disrupt the reading frame resulting 
in altered gene expression or create an alternative splice site resulting in an abnormal 
or inactive gene or gene product. The region of interest is GC rich as approximately 
73% of the base pairs being either guanine or cytosine in the 624 base pair region 
based on the predicted sequence. It is possible that additional methylation sites have 
been created in this GC rich region resulting in further suppression of HIC-1. 
Additionally, if the duplication being reported is a result of a translocation of the genetic 
material to another region in the genome, other genes may be potentially affected 
depending on the locus of the translocation. 
 
Free-Circulating DNA 
 The addition on chromosome 17p13.3 was identified in 100% of the DNA 
samples extracted from the endometriosis tissue but only in 75% of the DNA samples 
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extracted from the peripheral bloods. This may be due to free-circulating DNA (CFDNA) 
from the disease tissue cells in the blood.  The concept of CFDNA is not a new one. 
CFDNA of cancerous tumors as well as the CFDNA of an unborn fetus in the peripheral 
blood and serum of its mother can be detected in affected individuals and is now being 
used as a minimally invasive technique to detect multiple diseases. This is possible 
because CFDNA in many cancer patients has been demonstrated to harbor the same 
genetic alterations as the cancer tissue itself including hypermethylation, LOH, and copy 
number changes. In addition, the amount of CFDNA detected in these patients has 
been shown to be directly correlated with disease stage and severity. Two mechanisms 
have been postulated for how tumor CFDNA is released into the blood including 
apoptosis or necrosis and lysis of cells following their dissemination from disease tissue 
101. This is an interesting concept to consider in endometriosis as the disease tissue has 
been demonstrated to appear and proliferate in locations distant from the peritoneal 
cavity. This may be due to the transport of the disease cells to other regions of the body 
via the circulatory system. Further research involving the addition on chromosome 
17p13.3 in endometriosis patients is critical as a biomarker for the disease has yet to be 
identified and may allow for the development of a diagnostic test. 
 
Loss of Heterozygosity 
 Each region of LOH detected by the 180K platform was further investigated to 
see if any had been previously reported as being associated with conditions potentially 
related to endometriosis. All locations investigated had been previously reported in 
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cancer or other disease conditions as shown in Table 12. Of particular interest were 
regions of LOH on chromosomes 12p12, 13q22, and Xp21 which were shown to be 
present in ovarian cancer. The platform used in the current study detected only one 
common region of LOH in 2 patients on chromosome 4q33. This may be due to the 
small number of SNP probes included in this oligo/SNP combination type microarray 
relative to arrays designed to detect SNPs alone. Additional research using high 
resolution SNP arrays to investigate regions of LOH in endometriosis is necessary for a 
better understanding of these genetic alterations and their potential involvement in the 
disease process.   
Table 12 Regions of LOH as reported in the literature 
Region of LOH Disease Group 
2q24 Atherosclerosis Flouris et al. 
 Colon cancer Peng et al.  
4q33 Breast cancer Shivapurkar et al. 
 Colon cancer  Shivapurkar et al. 
 Distal stomach cancer Xu et al.  
5q23 Colon cancer Csiszar et al. 
 Esophageal cancer Attaran-Bandarabadi et al. 
 Lung cancer Shin et al. 
 Pharyngeal epithelial cancer Grati et al. 
6p23 B-cell non-Hodgkin's lymphoma Nagai et al. 
 Cervical cancer Zhang et al. 
 Nasopharyngeal carcinoma Shao et al. 
 Pulmonary sarcoidosis Demopoulos et al. 
10q21 Breast cancer Leighton et al. 
 Colon cancer Fawole et al. 
 Head and neck squamous cell carcinoma Beder et al. 
 Lung cancer Petersen et al. 
 Medulloblastoma Langdon et al. 
 Meningioma Krupp et al. 
 Osteosarcoma Smida et al. 
 Prostate cancer Srivastava et al. 
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Table 12 Continued 
11p12 Brain cancer Hu et al. 
 Lung cancer Iizuka et al. 
 Prostate cancer Dahiya et al. 
11q14 Brain cancer Hu et al. 
 Gastric cancer D'Adda et al. 
 Lung cancer Iizuka et al.  
 Neuroblastoma Carr et al. 
 Oral squamous cell carcinoma Zhou et al. 
 Squamous cell carcinoma of the head and 
neck 
Glavac et al. 
12p12 Acute lymphoblastic leukaemia Baccichet et al. 
 Colon cancer Wan et al. 
 Ovarian cancer Hatta et al. 
 Prostate cancer Kibel et al. 
13q22 Gastric cancer Jiao et al. 
 Nasopharyngeal carcinoma Zhou et al. 
 Ovarian/fallopian tube cancer Jongsma et al. 
 Testicular teratoma Jones et al. 
Xp11 Neuroendocrine lung carcinoma D'Adda et al. 
Xp21 Duchenne muscular dystrophy Fonseca-Mendoza et al.  
 Neuroendocrine lung carcinoma D'Adda et al. 
 Ovarian cancer Yang-Feng et al. 
 
Control Individuals 
To this point, genetic studies investigating endometriosis have been limited as 
ideal control individuals are difficult to obtain. It is likely that some of the “normal” control 
individuals used in this and other studies either have endometriosis and are 
asymptomatic or will develop the disease at some point in their lifetime. The criteria for 
inclusion in this study was that the individuals were over 30 years of age with no history 
of infertility as evidenced by having 2 or more children and no known family history of 
endometriosis. None of the controls were examined laparoscopically prior to this study.  
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The reality is that not all women who have endometriosis are infertile and many are 
asymptomatic and may not know they have the disease. This may account, in part, for 
the high number of controls that appear to have the additions of interest. Instead of 
attempting to include appropriate controls, most studies have looked for commonalities 
in the disease group of patients that have not been previously reported as being 
associated with another condition. The possible existence of microscopic endometriosis 
141-143 further complicates the issue. Microscopic endometriosis has been suggested to 
be present in physically normal, healthy tissue and is unable to be visualized without 
microscopy making even the standard laparoscopy a flawed diagnostic tool. Simply 
stated, physicians cannot diagnose, surgically remove, or treat what they cannot see; 
therefore, choosing the appropriate controls for studies involving endometriosis remains 
problematic at best.  
 
Polyploid Cells in Culture 
It was noted that the primary cell cultures from patient 1029 contained 
approximately 90% oversized metaphase cells, and subsequent karyotyping revealed 
24% of the metaphase spreads to be tetraploid. After initial observations were made on 
the aberrant metaphase cells, the cells were subcultured 5 times and frozen for later 
investigation. For karyotyping, the cells were thawed and cultured to the desired 
confluency before harvesting for karyotype analysis. The reduction in the number of 
polyploid cells with subculturing has been well documented and various mechanisms as 
to how it occurs have been put forth. Tetraploidy can occur as a result of several 
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mechanisms including cell fusion, mitotic slippage, and a failure of a cell to undergo 
cytokinesis 144, 145. Previous studies demonstrate that cells in culture tend to select 
against nondiploid cells 144, 146 reducing the number of aneuploid cells with each 
passage. A “G1 tetraploidy checkpoint” has been shown to act as a surveillance 
mechanism resulting in either cell cycle arrest or apoptosis of aneuploid cells 147 causing 
a decrease with each subsequent division. In addition, cell division time for tetraploid 
cells is greater than that of diploid cells resulting in fewer tetraploid cells over a given 
period. 
It is well known that aneuploidy is common in precancerous and cancerous 
tissues, and it has been demonstrated that women with ovarian endometriosis have an 
increased chance of developing ovarian cancer. In addition, studies indicate that 
ovarian endometriosis may be a precursor to ovarian cancer due to molecular 
similarities between the 2 disease states 148. The cells investigated in this portion of the 
study were obtained from endometriosis tissue of the ovary from a woman with stage III 
of the disease. The observation that the majority of metaphase cells in the primary 
culture appear to be tetraploid and that 24% remained tetraploid after 6 passages 
supports the notion that endometriosis is molecularly similar to cancer and may indicate 
ovarian endometriosis as a precursor to ovarian cancer.  
 
Copy Number Variant Size, Are We Missing Something? 
Many microarray analysis software programs allow the user to select a CNV cut-
off point in which the software will only report CNVs above the specified size. For many 
90 
 
high resolution platforms, the default cut-off size is approximately 200,000 base pairs. 
This reduces the CNV output as well as removes many polymorphisms simplifying the 
analysis; however, it eliminates small changes that may be of importance. To evaluate 
the potential significance of this observation, copy number variants for all patients in this 
study were recorded, and it was found that the majority of CNVs identified by the 
BlueFuse software were less than 200,000 base pairs in length. This is a vital piece of 
information as the majority of current studies use platforms that are not equipped to 
identify small chromosomal changes and may be missing critical pieces of information 
related to disease. Of the 7 studies summarized in the literature review that used 
microarray analysis to investigate CNVs in endometriosis patients, 3 used BAC probes, 
3 used FISH/metaphase CGH, and the most recent used a BeadChip SNP array.  BAC 
probes are generally over 100,000 base pairs in length and depending on the platform 
used, require multiple probes to be “out of range” to identify a gain or loss. FISH or 
metaphase CGH detects differences in fluorescence of probes hybridized directly to 
normal metaphase spreads and its resolution varies depending on the sensitivity of the 
software used to analyze the spreads. The Illumina HumanOmniExpressBeadchip used 
in the most recent publication on CGH in endometriosis has roughly 733,000 SNP 
probes spanning the genome at approximately every 2.2kb. In all cases, CNVs under 
several hundred thousand base pairs in length are unable to be detected. 
 This observation is not only important in relation to endometriosis but to all 
diseases in which CGH microarray technology is being used to look for genetic markers, 
genetic causes, or genetic links to disease. It has been well established that small 
genetic changes can be responsible for the development of disease such as in sickle 
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cell anemia wherein a single adenine to thymine change results in an altered gene 
product and disease onset. For this reason, we must question the findings of the studies 
in the literature that claim no genetic relationship to a specific disease based on low 
resolution platforms. Pathogenic microadditions and microdeletions may be present and 
overlooked in many cases due to technological shortcomings. As technology advances, 
more accurate and affordable testing is becoming available to researchers and many 
diseases need to be reassessed in terms of genetic alterations as causative agents. 
 
False Positives 
Array CGH has been observed to produce false-positives under certain 
conditions that may make interpretation of results difficult 149, 150. The conditions most 
often associated with the identification of false positives include probe coverage in G-C 
rich regions of the genome and “noisy arrays” that can result from the nonspecific 
hybridization of very small DNA fragments to random oligos. The region on 17p is 
considered G-C rich with 73% of the 624 base pair region containing guanines and 
cytosines based on the predicted sequence.  Unfortunately, there is no way to control 
for false-positives based on nucleotide content except for keeping in mind false-positive 
prone regions reported in the literature that include chromosomes 1p, 16p, 19, and 22 
35. 
 
 Also associated with false positives are “noisy” arrays in which DNA fragment 
sizes are too small to be sequence specific and bind to random locations throughout 
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the genome (Figure 22A). This may be caused by mishandling of DNA samples or 
DNA overdigestion. In this study, this issue was avoided by both confirming the DNA 
fragment size prior to hybridization using the Agilent Bioanalyzer and by viewing array 
parameters after each microarray run. “Noisy” arrays are identified by many probes 
outside of the accepted standard deviations identified by the red and green vertical 
lines in each array in Figure 22A. Any arrays with this type of appearance were 
discarded and the samples were rerun. Clean arrays are identified by the majority of 
probes inside of these lines as shown in Figure 22B.  
Figure 22 Microarray Runs, “Noisy” versus Clean…A. Noisy arrays are identified by 
the majority of probes outside of the accepted standard deviations B. Clean arrays are 
identified by the majority of probes inside of the accepted standard deviations 
A.       B.  
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Future Research 
 As this project progressed, a multitude of research projects have emerged that 
should be investigated in order to gain a clear understanding of the genetics of 
endometriosis. Sequencing the HIC-1 gene is imperative to our understanding of how it 
is involved in the disease mechanism. However, our attempts to sequence the HIC-1 
microaddition have so far been unsuccessful. Six DNA samples from endometriosis 
patients were sent to 2 sequencing facilities for targeted sequencing of the region 
containing the addition of interest. Neither was able to sequence the samples. It may be 
necessary to use more advanced methods of sequencing better suited for sequencing 
of G-C rich regions of the genome. Exome sequencing or whole genome sequencing 
should also be carried out as each would provide genome-wide sequence information 
including balanced changes in the DNA that cannot be identified by the platform utilized 
in this study.  
 The confirmation of the addition may be accomplished using polymerase chain 
reaction (PCR) and the Agilent Bioanalyzer. Isolation and amplification of a fragment 
obtained by using appropriate primers up- and downstream of the region of interest with 
PCR followed by analysis of fragment size using the Agilent Bioanalyzer may be 
informative. The fragment size should be larger than the predicted size reflecting the 
additions reported in this study.  
   The use of methylation arrays would reveal if HIC-1 is methylated or 
hypermethylated in endometriosis as expected. These arrays concentrate on G-C rich 
regions of the genome known to be methylated in a variety of cancers and are able to 
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identify single methylation sites. By examining DNA from both the blood and tissue from 
endometriosis patients, we may be able to gain a more clear understanding of how this 
epigenetic modification is involved in the disease mechanism of endometriosis. 
 
Research Conclusions and Summary 
 In this study we used oligonucleotide-array based comparative genomic 
hybridization to reveal an addition present on chromosome 17p13.3 in100% of 
endometriosis tissue samples assayed and in 75% of the peripheral blood samples from 
corresponding patients. This addition is located in the hypermethylated in cancer-1 gene 
and has not been previously associated with endometriosis.  
To this point, no definite genetic markers of endometriosis have been identified in 
either the blood or tissue of endometriosis patients leaving laparoscopy followed by 
pathological confirmation based on histology the most common method for diagnosis of 
the disease. If a genetic alteration is confirmed to be the cause or play a role in the 
development of the disease, women who are asymptomatic are unknowingly passing 
the disease gene to future generations. The discovery of a biomarker would allow for 
early detection of the disease resulting in a more accurate calculation of the number of 
women afflicted as well as the opportunity to avoid complications such as infertility with 
the proper medical intervention. 
It has been widely suggested that endometriosis is a multifactorial disease with 
proposed pathogenic mechanisms including retrograde menstruation, coelomic 
metaplasia, immunological factors, stem cells, surgical contamination, environmental 
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factors, and faulty genetics. While each of these mechanisms has convincing 
components, they are each lacking in some way. The majority of women experience 
retrograde bleeding, but why do only a portion develop endometriosis? Coelomic 
metaplasia may occur, but what initiates this cellular transformation?  Is there a defect 
in the immune system that renders it unable to recognize or eliminate misplaced 
endometrium?  If stem cells in circulation are totipotent, why would they necessarily 
become endometrial cells, and if they do become endometrial cells, why isn’t the 
immune system able to eradicate them?  Why would environmental factors cause the 
development of disease in only certain exposed individuals? Regardless of which 
hypothesis you buy into, it is certain that something is different either in the disease 
tissue itself or within the affected individual that allows endometriosis cells to attach, 
proliferate, and establish as disease.  It is probable that there are multiple explanations 
for what causes endometriosis; however, genetics is likely the underlying factor. In this 
study, we may have discovered a novel genetic aberration linked to endometriosis that 
may be useful in developing future diagnostic tests and treatments for the disease. 
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